{\rtf1 \ansi 
{\colortbl;
\red0\green0\blue0;
\red255\green255\blue255;
\red255\green0\blue0;
\red0\green255\blue0;
\red0\green0\blue255;
\red0\green255\blue255;
\red255\green0\blue255;
\red255\green255\blue0;
\red0\green0\blue128;
\red0\green128\blue128;
\red0\green128\blue0;
\red128\green0\blue128;
\red128\green0\blue0;
\red128\green128\blue0;
\red128\green128\blue128;
\red192\green192\blue192;
\red170\green170\blue170;
\red85\green85\blue85;
\red37\green37\blue37;
\red33\green33\blue33;
\red119\green119\blue119;
\red107\green107\blue106;
\red14\green86\blue140;
\red255\green255\blue102;
\red80\green80\blue80;
\red21\green137\blue21;
\red204\green204\blue204;
\red246\green246\blue246;
\red247\green247\blue247;
\red238\green238\blue238;
\red20\green93\blue164;
\red51\green51\blue51;
\red56\green124\blue43;
\red151\green151\blue151;
\red181\green79\blue104;
\red0\green114\blue54;
\red106\green144\blue39;
\red239\green122\blue2;
\red187\green187\blue187;
\red182\green231\blue243;
\red112\green112\blue112;
\red254\green254\blue0;
\red232\green233\blue232;
\red249\green249\blue249;
\red255\green248\blue96;
\red240\green240\blue240;
\red105\green105\blue105;
\red227\green227\blue227;
\red255\green210\blue183;
\red233\green233\blue233;
\red249\green250\blue251;
\red228\green231\blue232;
\red245\green245\blue245;
\red102\green0\blue102;
\red203\green203\blue203;
\red61\green61\blue61;
\red255\green255\blue174;
\red242\green242\blue242;
\red118\green118\blue118;
\red223\green223\blue223;
\red239\green239\blue239;
\red255\green255\blue198;
\red236\green236\blue236;
\red127\green127\blue127;
\red183\green242\blue206;
\red204\green255\blue255;
\red24\green140\blue181;
\red255\green194\blue211;
\red190\green190\blue252;
\red248\green161\blue28;
\red111\green34\blue109;
\red120\green162\blue47;
\red251\green252\blue255;
\red72\green72\blue72;
\red190\green195\blue204;
\red208\green208\blue208;
\red71\green120\blue194;
\red229\green243\blue255;
\red179\green218\blue255;
\red172\green172\blue172;
\red9\green56\blue84;
\red214\green214\blue214;
\red255\green255\blue204;
\red255\green204\blue0;
\red214\green9\blue9;
}
{\fonttbl {
\f0 Arial;}{
\f1 Symbol;}{
\f2 Times New Roman;}{
\f3 georgia;}{
\f4 sans-serif;}{
\f5 serif;}{
\f6 Source Sans Pro;}
}
{\*\generator Apache XML Graphics RTF Library;}
\fet0 \ftnbj \paperw12240 \paperh15840 \margt1080 \margb1080 \margl1080 \margr1080 \headery720 \footery720 \itap0 \cols2 
\sectd {\header {
{\trowd \ltrrow \trleft0 
\clpadb60 \clpadfb3 \clpadl400 \clpadfl3 \clbrdrt \clbrdrb \brdrcf17 \brdrw20 \brdrs \clbrdrl \trql \clvertalb \clwWidth9380 \cellx9380 
\clpadb60 \clpadfb3 \clpadl400 \clpadfl3 \clbrdrt \clbrdrb \brdrcf17 \brdrw20 \brdrs \clbrdrr \trql \clwWidth700 \cellx10080 
\intbl 
{\b0 \cf1 \f0 \ri0 \i0 \ql \fs18 \li0 
{\b0 \cf1 \f0 \ul0 \strike0 \i0 \fs18 
}
{\b1 \cf18 \f0 \i0 \fs18 
{\b1 \cf18 \f0 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Pernix Ireland Pain DAC v. Alvogen Malta Operations Ltd., Not Reported in Fed. Supp....
}
}
{\b0 \cf1 \f0 \ul0 \strike0 \i0 \fs18 
}
}\b0 \cf1 \f0 \ri0 \ul0 \strike0 \i0 \ql \fs18 \li0 \sa0 \sb0 \intbl \cell \intbl 
{\qr \b0 \cf1 \f0 \ri0 \i0 \fs18 \li0 
}\qr \b0 \cf1 \f0 \ri0 \i0 \fs18 \li0 \intbl \cell \row }
{\trowd \lastrow \trleft0 
\clbrdrb \clbrdrl \trql \clwWidth10080 \cellx10080 
\intbl 
{\b0 \cf1 \f0 \ri0 \i0 \ql \fs18 \li0 
}\b0 \cf1 \f0 \ri0 \i0 \ql \fs18 \li0 \intbl \cell \row }}\par }{\footer {
{\trowd \lastrow \trleft0 
\clpadl60 \clpadfl3 \clbrdrt \brdrcf17 \brdrw20 \brdrs \clbrdrb \clbrdrl \trql \clvertalb \clwWidth9300 \cellx9300 
\clpadl60 \clpadfl3 \clbrdrt \brdrcf17 \brdrw20 \brdrs \clbrdrb \clbrdrr \trql \clwWidth700 \cellx10000 
\intbl 
{\b0 \cf17 \f0 \ri0 \i0 \ql \fs20 \li0 
{\b0 \cf17 \f0 \ul0 \strike0 \i0 \fs20 
}
{\*\shppict {\pict \pngblip \picw78 \pich10 \picwgoal1170 \pichgoal150 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}}
{\b0 \cf17 \f0 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u169\'3f 2021 Thomson Reuters. No claim to original U.S. Government Works.
}
}\b0 \cf17 \f0 \ri0 \ul0 \strike0 \i0 \ql \fs20 \li0 \sa0 \sb0 \intbl \cell \intbl 
{\qr \b0 \cf17 \f0 \ri0 \i0 \fs20 \li0 
{\b0 \i0 \ul0 \fs20 \f0 \chpgn }
}\qr \b0 \cf17 \f0 \ri0 \ul0 \strike0 \i0 \fs20 \li0 \intbl \cell \row }}\par }
{\b0 \cf1 \f2 \ri0 \par}\sect\sbknone\pgncont\cols2{\ids0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_document_53}{\*\bkmkend co_document_53}
{\b0 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart I593a96e0593911e89034f60e1699ddbe_Target}{\*\bkmkend I593a96e0593911e89034f60e1699ddbe_Target}
\par 
}
{\b0 \qc \cf1 \f3 \ri0 \i0 \fs20 \li0 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs20 \sa0 \sb100 
2018 WL 2225113
\par 
}
}
{\b0 \qc \cf1 \f3 \ri0 \i0 \fs20 \li0 
{\b0 \qc \cf1 \f3 \ri0 \i0 \fs20 \li0 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Only the Westlaw citation is currently available.
\par 
}
}
}
{\b0 \qc \cf1 \f3 \ri0 \i0 \fs20 \li0 
{\b0 \qc \cf1 \f3 \ri0 \i0 \fs20 \li0 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
United States District Court, D. Delaware.
\par 
}
}
}
{\b0 \qc \cf19 \f3 \ri120 \i0 \fs24 \li120 
{\b0 \qc \cf19 \f3 \ri120 \i0 \fs24 \li120 
{\b0 \qc \cf19 \f3 \ri120 \i0 \fs24 \li120 
{\b0 \cf19 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb240 
PERNIX IRELAND PAIN DAC and Pernix Therapeutics, LLC, Plaintiffs,
\par 
}
}
{\b0 \qc \cf19 \f3 \ri120 \i0 \fs24 \li120 
{\b0 \cf19 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
v.
\par 
}
}
{\b0 \qc \cf19 \f3 \ri120 \i0 \fs24 \li120 
{\b0 \cf19 \f3 \ul0 \strike0 \i0 \fs24 \sa240 \sb0 
ALVOGEN MALTA OPERATIONS LTD., Defendant.
\par 
}
}
}
}
{\b0 \qc \cf1 \f2 \ri0 \i0 \fs20 \li0 
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \qc \cf1 \f3 \ri0 \i0 \fs20 \li200 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Civil Action No. 16\u8211\'3f139\u8211\'3fWCB
\par 
}
}
}
{\b0 \cf1 \f3 \i0 \fs20 
{\b0 \qc \cf1 \f3 \ri0 \i0 \fs20 \li200 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
|
\par 
}
}
{\b0 \qc \cf1 \f3 \ri0 \i0 \fs20 \li200 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs20 \sa200 \sb0 
Signed 05/15/2018
\par 
}
}
}
}
{\b1 \cf20 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_attorneysAndLawFirms_53}{\*\bkmkend co_attorneysAndLawFirms_53}
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb200 
Attorneys and Law Firms
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0177211801&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Michael P. Kelly
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0444922201&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Benjamin A. Smyth
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0359097501&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Daniel M. Silver
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, McCarter & English, LLP, Wilmington, DE, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0403664801&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Brendan M. O\rquote Malley
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Pro Hac Vice, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0273561301&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Christopher P. Borello
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Pro Hac Vice, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0486955001&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Christopher J. Stankus
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Pro Hac Vice, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0497415099&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
David G. Varghese
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Pro Hac Vice, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0232949001&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Dominick A. Conde
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Pro Hac Vice, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0460560301&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Josh Calabro
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Pro Hac Vice, for Plaintiffs.
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0452391501&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
David M. Fry
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0496923499&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Nathan Roger Hoeschen
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Shaw Keller LLP, Wilmington, DE, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0369710001&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Thomas K. Hedemann
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Pro Hac Vice, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0320649301&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Chad A. Landmon
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Pro Hac Vice, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0491761599&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Christopher M. Gallo
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Pro Hac Vice, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0324418301&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Edward M. Mathias
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Pro Hac Vice, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0209041801&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Matthew J. Becker
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Pro Hac Vice, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0429894501&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Seth I. Heller
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
, Pro Hac Vice, for Defendant.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf20 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_opinion_53}{\*\bkmkend co_opinion_53}
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ib5e1b702a3fe11e99db4e63a0d33c}{\*\bkmkend co_anchor_Ib5e1b702a3fe11e99db4e63a0d33c}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ib5f9abd1a3fe11e99db4e63a0d33c}{\*\bkmkend co_anchor_Ib5f9abd1a3fe11e99db4e63a0d33c}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ib5f9abd1a3fe11e99db4e63a0d33c}{\*\bkmkend co_anchor_Ib5f9abd1a3fe11e99db4e63a0d33c}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa200 \sb800 
MEMORANDUM OPINION AND ORDER
\par 
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0112582701&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
WILLIAM C. BRYSON
}}}
\sa200 
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb200 
, UNITED STATES CIRCUIT JUDGE
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_1_53}{\*\bkmkend co_pp_sp_999_1_53}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Before the Court are various pretrial motions filed by plaintiffs Pernix Ireland Pain DAC and Pernix Therapeutics (collectively, \u8220\'3fPernix\u8221\'3f) and defendant Alvogen Malta Operations Ltd. (\u8220\'3fAlvogen\u8221\'3f). The motions include 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Defendant Alvogen Malta Operations Ltd.\u8217\'3fs Motion for Summary Judgment of Invalidity Under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Dkt. No. 111; 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Plaintiffs\u8217\'3f Motion for Summary Judgment of No Invalidity Under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Dkt. No. 114; 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Defendant Alvogen Malta Operations Ltd.\u8217\'3fs Motion for Summary Judgment of Invalidity by Anticipation
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Dkt. No. 115; 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Plaintiffs\u8217\'3f Motion for Summary Judgment of Infringement
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Dkt. No. 118; and 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Alvogen Malta Operations Ltd.\u8217\'3fs Motion To Strike and Exclude Pernix\u8217\'3fs Late\u8211\'3fDisclosed Infringement Theory
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Dkt. No. 125. The Court heard argument on the motions on May 11, 2018. Alvogen\u8217\'3fs motion for summary judgment of invalidity under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
section
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is DENIED, and Pernix\u8217\'3fs motion for summary judgment of no invalidity under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
section
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is GRANTED. Alvogen\u8217\'3fs motion for summary judgment of invalidity by anticipation is DENIED. Pernix\u8217\'3fs motion for summary judgment of infringement is DENIED. Alvogen\u8217\'3fs motion to strike Pernix\u8217\'3fs late-disclosed infringement theory is GRANTED.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ib5fb0b61a3fe11e99db4e63a0d33c}{\*\bkmkend co_anchor_Ib5fb0b61a3fe11e99db4e63a0d33c}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
BACKGROUND
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In this Hatch\u8211\'3fWaxman Act lawsuit arising under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=SP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_9e660000185f2" }{\fldrslt 
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. \u167\'3f 271(e)(2)(A)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Pernix has accused Alvogen of patent infringement. Pernix\u8217\'3fs claims of infringement are based on Alvogen\u8217\'3fs filing of its Abbreviated New Drug Application (\u8220\'3fANDA\u8221\'3f) with the United States Food and Drug Administration (\u8220\'3fFDA\u8221\'3f), seeking authorization to sell 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3bd96eea475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hydrocodone
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 bitartrate extended release capsules as generic versions of Pernix\u8217\'3fs 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3bd96eea475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hydrocodone
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 formulation, which is sold under the name Zohydro.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
For purposes of the trial in this case, Pernix has asserted nine claims from two of the patents that protect Pernix\u8217\'3fs Zohydro product. The asserted claims are claims 1\u8211\'3f4, 11, 12, 17, and 19 of Pernix\u8217\'3fs 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038345875&pubNum=0004074&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=PA&docFamilyGuid=I0828fca0db3d11e58e7d9ad815219c93&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
U.S. Patent No. 9,265,760 (\u8220\'3fthe \u8217\'3f760 patent\u8221\'3f)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, and claim 1 of Pernix\u8217\'3fs 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038908796&pubNum=0004074&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=PA&docFamilyGuid=I994d8600212511e6a515da1203855afb&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
U.S. Patent No. 9,339,499 (\u8220\'3fthe \u8217\'3f499 patent\u8221\'3f)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Pernix\u8217\'3fs patents are directed to methods of treating pain in patients with 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, i.e. comprised liver function. The patents explain that the liver is responsible for most of the body\u8217\'3fs capacity to metabolize opioids. Because of the importance of the liver in clearing opioids from the body, patients with 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 who take opioids for pain relief are often prescribed reduced dosages of the drugs so as to avoid an unsafe build-up of the opioids in the patients\u8217\'3f systems. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038345875&pubNum=0004074&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=PA&docFamilyGuid=I0828fca0db3d11e58e7d9ad815219c93&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f760 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, col. 2, ll. 41\u8211\'3f66.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The patented invention encompasses formulations of extended release 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3bd96eea475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hydrocodone
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 that have release profiles that are similar for both healthy and hepatically impaired patients. For that reason, the starting dose does not need to be adjusted for a patient with 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 relative to one without 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
All nine of the claims asserted in this case recite a \u8220\'3fmethod of treating pain in a patient having mild or moderate 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
,\u8221\'3f and all nine include the step of \u8220\'3fadministering to the patient having mild or moderate 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 an oral dosage unit having 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3bd96eea475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hydrocodone
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 bitartrate as the only active ingredient, wherein the dosage unit comprises an extended release formulation of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3bd96eea475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hydrocodone
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 bitartrate.\u8221\'3f
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_2_53}{\*\bkmkend co_pp_sp_999_2_53}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*2
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 While the claims generally cover the same subject matter, they differ in a few respects, and can be separated into three groups. First, in addition to the \u8220\'3fadministering\u8221\'3f step, claim 1 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038345875&pubNum=0004074&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=PA&docFamilyGuid=I0828fca0db3d11e58e7d9ad815219c93&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f760 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 includes the limitation \u8220\'3fwherein the starting dose is not adjusted relative to a patient without 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.\u8221\'3f Second, claims 2\u8211\'3f4 and 11 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038345875&pubNum=0004074&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=PA&docFamilyGuid=I0828fca0db3d11e58e7d9ad815219c93&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f760 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 all depend on claim 1, and each of those dependent claims recites different components of the release profile, i.e., the way a patient\u8217\'3fs body breaks down the drug, as measured by the maximum concentration of drug in the patient\u8217\'3fs blood (C
}
{\b0 \cf1 \f2 \i0 \fs16 
{\sub \b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
max
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
) and the measure of total exposure of the drug over time (AUC
}
{\b0 \cf1 \f2 \i0 \fs16 
{\sub \b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
0\u8211\'3finf.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
). Specifically, each claim adds that the dosage unit does not result in increasing the maximum or total exposure of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3bd96eea475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hydrocodone
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 in subjects with mild or moderate 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 by more than a certain amount relative to subjects not suffering from mild or moderate 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Finally, claims 12, 17, and 19 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038345875&pubNum=0004074&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=PA&docFamilyGuid=I0828fca0db3d11e58e7d9ad815219c93&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f760 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, and claim 1 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038908796&pubNum=0004074&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=PA&docFamilyGuid=I994d8600212511e6a515da1203855afb&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f499 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, are likewise directed to methods of treating pain in a patient having mild or moderate 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Each of those claims includes limitations regarding the release profile of the dosing unit, but that group of claims does not include or incorporate a limitation that the starting dose is not adjusted relative to a patient without 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ib5fe66c1a3fe11e99db4e63a0d33c}{\*\bkmkend co_anchor_Ib5fe66c1a3fe11e99db4e63a0d33c}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
DISCUSSION
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
I. Alvogen\u8217\'3fs Motion to Strike
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Alvogen\u8217\'3fs motion to strike is addressed to only the first two sets of claims\u8212\'3fclaims 1\u8211\'3f4 and 11 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038345875&pubNum=0004074&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=PA&docFamilyGuid=I0828fca0db3d11e58e7d9ad815219c93&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f760 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Alvogen contends that in Pernix\u8217\'3fs recently filed motion for summary judgment of infringement, Pernix added a theory of infringement that was not disclosed in its amended infringement contentions or discussed in the report of its infringement expert. Pernix\u8217\'3fs new theory, according to Alvogen, is that a patient can directly infringe claims 1\u8211\'3f4 and 11 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038345875&pubNum=0004074&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=PA&docFamilyGuid=I0828fca0db3d11e58e7d9ad815219c93&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f760 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 acting alone, and that it is not necessary for Pernix to show joint infringement by both the prescribing physician and the patient in order to prove direct infringement of those claims. Pernix contends that in addition to its theory of joint infringement by the physician and patient, it has consistently asserted the theory that the patient can infringe alone\u8212\'3fwithout the need for joint action by the physician\u8212\'3fsince the outset of the case and that it should not be foreclosed from presenting that theory at trial.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ib5ff5121a3fe11e99db4e63a0d33c}{\*\bkmkend co_anchor_Ib5ff5121a3fe11e99db4e63a0d33c}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
A. Pernix\u8217\'3fs Theories of Direct Infringement
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The two theories of direct infringement of claims 1\u8211\'3f4 and 11 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038345875&pubNum=0004074&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=PA&docFamilyGuid=I0828fca0db3d11e58e7d9ad815219c93&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f760 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 on which Pernix seeks to rely are: (1) joint direct infringement by the physician and the patient; and (2) single-party direct infringement by the patient alone. Under the theory of joint direct infringement, Pernix contends that the physician and the patient jointly infringe claims 1\u8211\'3f4 and 11 when the physician prescribes and directs a hepatically impaired patient to take extended release 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3bd96eea475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hydrocodone
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 bitartrate, in which the starting dose is not adjusted relative to a patient without 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, and the patient takes the drug as directed. Under the theory of single-party direct infringement, Pernix contends that the patient alone, when taking the unadjusted dose of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3bd96eea475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hydrocodone
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 bitartrate, directly infringes those claims.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Pernix did not explicitly spell out any theory of infringement in the complaint. The complaint, however, referred to direct infringement by \u8220\'3fphysicians, health care providers, and/or patients,\u8221\'3f and thus was broad enough to encompass both the joint-infringement and the patient-alone theories of direct infringement. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Second Am. Compl., Dkt. No. 37, \u182\'3f 40; 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u182\'3f 41 (\u8220\'3fOn information and belief, Alvogen specifically intends that physicians, health care providers, and/or patients will use the Alvogen Generic Product in accordance with the instructions provided by Alvogen to directly infringe one or more claims of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038345875&pubNum=0004074&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=PA&docFamilyGuid=I0828fca0db3d11e58e7d9ad815219c93&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f760
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 [patent]\u8221\'3f); 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u182\'3f 48 (\u8220\'3fThe use of the Alvogen Generic Product by physicians, health care providers, and/or patients prior to patent expiry will directly infringe one or more claims of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038345875&pubNum=0004074&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=PA&docFamilyGuid=I0828fca0db3d11e58e7d9ad815219c93&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f760 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.\u8221\'3f).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In its initial infringement claim charts, Pernix made clear that its theory of liability was based on induced infringement. However, Pernix did not explicitly state whether the direct infringement necessary to establish liability for induced infringement was the product of direct infringement by the patient alone or joint infringement by the patient and the prescribing physician. Instead, Pernix\u8217\'3fs infringement contentions focused on Alvogen\u8217\'3fs acts of inducement; Pernix asserted that \u8220\'3fAlvogen\u8217\'3fs Draft Label provides instructions for administering its proposed generic product to treat pain in patients having mild or moderate 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.\u8221\'3f Dkt. No. 125\u8211\'3f2, Ex. A, at 1. As to the requirement that the \u8220\'3fstarting dose is not adjusted relative to a patient without 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
,\u8221\'3f the infringement contentions stated: \u8220\'3fAlvogen\u8217\'3fs Draft Label instructs physicians that the starting dose of Alvogen\u8217\'3fs proposed generic product is not adjusted for patients with mild or moderate 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 relative to a patient without 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.\u8221\'3f 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
\par 
}
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_3_53}{\*\bkmkend co_pp_sp_999_3_53}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*3
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 During the claim construction process, the parties focused on two phrases from the claims: \u8220\'3fadministering to the patient\u8221\'3f and \u8220\'3fwherein the starting dose is not adjusted relative to a patient without 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.\u8221\'3f Pernix argued that \u8220\'3fadministering\u8221\'3f meant \u8220\'3fprescribing, dispensing, giving or taking (such that what is prescribed, dispensed, given or taken is actually taken into the patient\u8217\'3fs body.\u8221\'3f 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 The Parties\u8217\'3f Revised Final Joint Claim Chart, Dkt. No. 58\u8211\'3f1, at 1. Pernix argued that the \u8220\'3fwherein the starting dose is not adjusted\u8221\'3f phrase was a limitation that meant \u8220\'3fthe dose prescribed to a patient with mild or moderate 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 when initiating treatment is not reduced due to that 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 relative to the dose prescribed to a patient without 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 when initiating treatment.\u8221\'3f 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 2.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In both the briefing and the argument on the claim construction dispute, Pernix made clear that it construed the \u8220\'3fwherein the starting dose is not adjusted\u8221\'3f limitation to be directed to the actions of the prescribing physician. For example, in its answering claim construction brief, Pernix wrote that the disputed phrase \u8220\'3fis a step that is integral to the claimed method and its infringement, requiring action to be taken by the physician, namely administering (prescribing) the same starting dose of drug to a hepatically impaired patient that would be administered to one that is 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
not
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 impaired.\u8221\'3f Dkt. No. 65, at 2. Similarly, in the claim construction oral argument before Judge Sleet, Pernix contended that the \u8220\'3fwherein the starting dose is not adjusted\u8221\'3f limitation \u8220\'3ftells a physician how to dose the drug.\u8221\'3f Dkt. No. 68, at 5:24\u8211\'3f25; 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
see also
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 13:10\u8211\'3f14 (\u8220\'3f \u8216\'3f[W]herein the starting dose is not adjusted relative to a patient without 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f tells the physician to give the same dose to a hepatically impaired patient that would be given to an unimpaired person.\u8221\'3f); 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 14:12\u8211\'3f14 (\u8220\'3f[T]his language is the only language in the claim that tells the physician what to do and tells an accused infringer why they infringe.\u8221\'3f).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Judge Sleet issued a claim construction order construing the two disputed terms on August 3, 2017. Dkt. No. 69. First, he construed the term \u8220\'3fadministering\u8221\'3f to mean \u8220\'3fdelivering into the body.\u8221\'3f 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1. When adopting that construction, he rejected Pernix\u8217\'3fs argument that \u8220\'3fadministering\u8221\'3f should include the acts of prescribing or dispensing (by a physician or health care provider). Second, he construed the phrase \u8220\'3fstarting dose is not adjusted relative to a patient without 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8221\'3f to mean that \u8220\'3fthe dose prescribed to a patient with mild or moderate 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 when initiating treatment is not reduced due to that 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 relative to the dose prescribed to a patient without 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 when initiating treatment.\u8221\'3f 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 2. In so doing, Judge Sleet adopted Pernix\u8217\'3fs proposed construction of that term. He also agreed with Pernix\u8217\'3fs position that the \u8220\'3fstarting dose is not adjusted\u8221\'3f phrase is a limitation of the claim. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 2 n.2.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Following the claim construction order, Pernix served an amended infringement claim chart for claims 1\u8211\'3f4 and 11 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038345875&pubNum=0004074&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=PA&docFamilyGuid=I0828fca0db3d11e58e7d9ad815219c93&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f760 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Dkt. No. 125\u8211\'3f3, at 1\u8211\'3f2. The only change made in the new infringement contentions for those claims was the addition of the following language for both the \u8220\'3fadministering\u8221\'3f and \u8220\'3fstarting dose is not adjusted\u8221\'3f limitations: \u8220\'3fPhysicians direct and/or control their patients\u8217\'3f administration of a starting dose of Alvogen\u8217\'3fs proposed generic product in such a manner as to condition the receipt of treatment on the patient\u8217\'3fs administration of the prescribed starting dose. Further, the physician establishes the manner and timing of the patients\u8217\'3f administration of the starting dose.\u8221\'3f 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Ex. A, at 1\u8211\'3f2.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_4_53}{\*\bkmkend co_pp_sp_999_4_53}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*4
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 When it filed its brief in support of its motion for summary judgment of infringement in March 2018, Pernix stated for the first time that it intended to prove the direct infringement component of induced infringement either by showing direct infringement by the patient alone or by showing joint direct infringement by the patient and the prescribing physician. Dkt. No. 120. Alvogen immediately protested by filing the present motion to strike and exclude Pernix\u8217\'3fs theory that direct infringement could be shown by proof of direct infringement by the patient alone. Dkt. No. 125.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In its motion, Alvogen argues that the amended infringement contentions effectively abandoned that theory of direct infringement and that it was too late for Pernix to attempt to revive it. Pernix responds that it never withdrew the theory of patient-only direct infringement, because it never withdrew any of the language of its original infringement contentions. Instead, Pernix contends that it merely added new language to the infringement contentions after Judge Sleet\u8217\'3fs claim construction order and thus preserved both the \u8220\'3fpatient-only\u8221\'3f theory of direct infringement and the \u8220\'3fpatient-physician\u8221\'3f theory of joint direct infringement. 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Dkt. No. 148, at 4\u8211\'3f6.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ib605b9c1a3fe11e99db4e63a0d33c}{\*\bkmkend co_anchor_Ib605b9c1a3fe11e99db4e63a0d33c}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
B. Pernix Has Not Preserved a \u8220\'3fPatient\u8211\'3fOnly\u8221\'3f Theory of Direct Infringement
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The Court agrees with Alvogen that Pernix may not pursue its patient-only theory of direct infringement. Until Pernix filed its summary judgment motion in March of this year, Pernix\u8217\'3fs position as to infringement of claims 1\u8211\'3f4 and 11 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038345875&pubNum=0004074&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=PA&docFamilyGuid=I0828fca0db3d11e58e7d9ad815219c93&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f760 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 was based on a theory of joint direct infringement by both the patient and the physician. Pernix\u8217\'3fs amended infringement contentions contained no reference to the patient-only theory of direct infringement. Instead, the amended contentions focused on the role of the physician in the alleged direct infringement; thus, joint infringement was the only theory of direct infringement set forth in the amended infringement contentions.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Similarly, the arguments made by Pernix\u8217\'3fs counsel during the claim construction process make quite clear that Pernix\u8217\'3fs theory of direct infringement contemplated that the physician would be the person who would be responsible for determining that the \u8220\'3fstarting dose is not adjusted relative to a patient without 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.\u8221\'3f 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Dkt. No. 65, at 2 (The language of the \u8220\'3fstarting dose is not adjusted\u8221\'3f limitation requires \u8220\'3faction to be taken by the physician,\u8221\'3f i.e., prescribing \u8220\'3fthe same starting dose of drug to a hepatically impaired patient that would be administered to one that is not impaired.\u8221\'3f).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The absence of any reference to the patient-only theory of direct infringement in the report of Dr. Gudin, Pernix\u8217\'3fs infringement expert, is particularly telling. In the portions of his report directed to the issue of direct infringement, Dr. Gudin repeatedly emphasized that the physician \u8220\'3fwill direct a patient with mild or moderate 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 to take the same starting dose ... as a patient without 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
,\u8221\'3f and that \u8220\'3fthe dosage form will be self-administered by the patient as directed by the physician.\u8221\'3f Dkt. No. 125\u8211\'3f4 \u182\'3f 69; 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
see also
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u182\'3f 70 (\u8220\'3f[A] physician following the Alvogen Draft Label does treat patients, and it is the physician who determines the starting dose to be given, and the physician who controls the dose that the patient will receive through writing a prescription for a particular dosage strength.\u8221\'3f); 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u182\'3f 73 (\u8220\'3f[W]hen a physician directs a patient with mild or moderate 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 to take a particular dose of the Alvogen Proposed ANDA Product, and the patient takes that dose, the physician and patient jointly practice the claimed method.\u8221\'3f); 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u182\'3f 77 (\u8220\'3fWhen a physician directs a patient with mild or moderate 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 to take a particular dose of the Alvogen Proposed ANDA Product, and the patient takes that dose, the physician and patient jointly practice \u8216\'3fa method of treating pain in a patient having mild or moderate 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.\u8217\'3f \u8221\'3f); 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u182\'3f 83 (\u8220\'3fIn summary, all of the elements of claim 1 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038345875&pubNum=0004074&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=PA&docFamilyGuid=I0828fca0db3d11e58e7d9ad815219c93&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f760 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 are met when physicians direct patients with mild or moderate 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 to self-administer Alvogen\u8217\'3fs Proposed ANDA Product according to the instructions in the Alvogen Draft Label, and patients self-administer the Alvogen Proposed ANDA Product according to the physician\u8217\'3fs instructions.\u8221\'3f).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_5_53}{\*\bkmkend co_pp_sp_999_5_53}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*5
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Pernix asserts that Dr. Gudin\u8217\'3fs report contains references to the patient-only theory of direct infringement, but the citations to the report on which Pernix relies do not support that assertion. Dkt. No. 148, at 5\u8211\'3f6. Pernix first cites a section of Dr. Gudin\u8217\'3fs report in which he summarized general legal principles as he understood them. 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
He stated that \u8220\'3fI further understand from counsel that if no single actor performs all steps of the method of treatment claims (
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
e.g.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, a physician determines the dose to be administered, but the patient self-administers the drug), direct infringement occurs if the acts of one actor are attributable to the other.\u8221\'3f Dkt. No. 125\u8211\'3f4 \u182\'3f 49. Contrary to Pernix\u8217\'3fs argument, that general statement of law does not constitute a contention that in this case the patient alone is directly infringing the relevant 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038345875&pubNum=0004074&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=PA&docFamilyGuid=I0828fca0db3d11e58e7d9ad815219c93&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f760 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 claims. In fact, later in that same paragraph, Dr. Gudin made clear that the application of the general principles he recited was to joint direct infringement by the physician and the patient. He wrote: \u8220\'3fAs discussed in further detail below, for the claims of the Patents\u8211\'3fin\u8211\'3fSuit, the patient\u8217\'3fs receipt of the prescribed dose of drug (through the doctor\u8217\'3fs prescription) is conditioned upon the understanding that the patient will use the drug as directed, and it is the physician who dictates the manner and timing of the patient\u8217\'3fs self-administration of the drug.\u8221\'3f 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
\par 
}
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Pernix also cites a portion of Dr. Gudin\u8217\'3fs report in which he stated that he understood Alvogen\u8217\'3fs argument to be that it does not infringe the claims of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038345875&pubNum=0004074&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=PA&docFamilyGuid=I0828fca0db3d11e58e7d9ad815219c93&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f760 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 because different actors perform the separate steps of selecting a starting dose and administering the drug. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u182\'3f 72. Dr. Gudin\u8217\'3fs answer to that contention is telling. He did not respond by saying that the patient infringes through his conduct alone, but instead stated that Alvogen\u8217\'3fs argument ignores that \u8220\'3fwhen a physician directs a patient with mild or moderate 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 to take a particular dose of the Alvogen Proposed ANDA Product, and the patient takes that dose, the physician and patient jointly practice the claimed method.\u8221\'3f 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u182\'3f 73. It is thus clear that, as of the time that it submitted its amended infringement contentions and Dr. Gudin\u8217\'3fs expert report, Pernix was not pursuing a patient-only theory of direct infringement, even as an alternative to the joint direct infringement theory.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ib60a74b1a3fe11e99db4e63a0d33c}{\*\bkmkend co_anchor_Ib60a74b1a3fe11e99db4e63a0d33c}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
C. Pernix\u8217\'3fs Failure to Raise Its Patient\u8211\'3fOnly Theory is Not Excused
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Pernix\u8217\'3fs final argument is that, even if it did not present a patient-only direct infringement theory in its amended infringement contentions and in Dr. Gudin\u8217\'3fs expert report, it should be permitted to raise that theory now, even though discovery in the case is closed, expert reports and depositions have been completed, and trial is only a month away. In so arguing, Pernix relies on a line of cases holding that a sanction such as excluding a theory of infringement is an extreme sanction that should not lightly be imposed, and that the following factors should be considered in determining whether to bar a party from asserting a belatedly presented theory: (1) prejudice or surprise to the objecting party; (2) the ability of that party to cure the surprise; (3) whether the default would disrupt the orderly and efficient presentation of the case; and (4) bad faith or willfulness on the part of the defaulting party. Dkt. No. 148, at 3 (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1977123224&pubNum=0000350&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_350_904&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_350_904" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Meyers v. Pennypack Woods Home Ownership Ass\u8217\'3fn
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 559 F.2d 894, 904\u8211\'3f05 (3d Cir. 1977)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 ); 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
see also
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 6\u8211\'3f11.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The first answer to Pernix\u8217\'3fs argument is that, quite apart from any default on Pernix\u8217\'3fs part, the claim language does not support a patient-only theory of direct infringement. Relying on the recent opinion from this district in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2042879162&pubNum=0007903&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Orexigen Therapeutics, Inc. v. Actavis Laboratories FL, Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 282 F. Supp. 3d 793 (D. Del. 2017)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Pernix contends that although the \u8220\'3fwherein the starting dose is not adjusted\u8221\'3f phrase is a limitation of claims 1\u8211\'3f4 and 11 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038345875&pubNum=0004074&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=PA&docFamilyGuid=I0828fca0db3d11e58e7d9ad815219c93&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f760 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, it merely states a background condition for the administration of the hydrocodone composition, and that identifying the starting dose \u8220\'3fis a predicate to performing the claimed administering step, which is performed by the patient.\u8221\'3f Dkt. No. 120, at 13; 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
see also
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fWhile a physician must determine and prescribe the dose of the drug product before a patient can administer it, as in 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Orexigen
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, that action will already have been completed prior to performance of the claimed method (
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
i.e.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, prior to the patient \u8216\'3fadministering\u8217\'3f the drug product).\u8221\'3f).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_6_53}{\*\bkmkend co_pp_sp_999_6_53}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*6
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 That argument goes nowhere. It is certainly true that the physician must make a determination regarding the dose that the patient should take before the patient performs the administration step. But it is commonplace for the steps in a method claim to have to be performed in a particular order in order for the method to work as intended. If the phrase \u8220\'3fstarting dose is not adjusted relative to a patient without 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8221\'3f had been drafted to read \u8220\'3fthe prescribing physician does not adjust the starting dose relative to a patient without 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
,\u8221\'3f there would be no question that infringement would require joint action by the physician and the patient. The fact that the claim limitation calls upon the physician to refrain from doing something (not adjusting the dosage limitation) instead of affirmatively doing something (such as directing that the dosage be cut in half for hepatically impaired patients) does not alter the fact that action by the physician is required to infringe the claim. The step is simply written in the passive voice in order not to limit the identity of the party that determines that an unadjusted dose should be given to the patient with 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Orexigen
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 case on which Pernix relies is inapplicable. In that case, the pertinent claim language referred to administering a compound to a person \u8220\'3fwho has been diagnosed as suffering from overweight or 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib521aefe475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
obesity
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2042879162&pubNum=0007903&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_7903_812&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_7903_812" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
282 F. Supp. 3d at 812
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Judge Andrews found that the claims containing that language involved \u8220\'3fthe single step of administering the drug to a patient who has already been diagnosed,\u8221\'3f and that the diagnosis was not a step of the claimed methods. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 In this case, by contrast, the step of not adjusting the starting dose relative to a patient without 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is properly characterized as both a limitation and a step of the methods recited in the asserted claims.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Even setting aside the legal flaw in Pernix\u8217\'3fs patient-only direct infringement theory, the Court would reject Pernix\u8217\'3fs argument that it should be allowed, at this late juncture, to present a new patient-only theory of direct infringement. In light of Pernix\u8217\'3fs consistent reliance on the theory joint direct infringement by patient and physician, and in particular in light of Pernix\u8217\'3fs expert\u8217\'3fs failure to present a theory of patient-only direct infringement, it would be unfair to require Alvogen to respond to that theory at trial. Alvogen\u8217\'3fs expert did not address that theory, and Alvogen (understandably) did not conduct discovery directed at that theory, which it otherwise could have done, such as by examining Pernix\u8217\'3fs expert on that issue and having its own expert address the issue.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Pernix argues that it is inconsequential that Alvogen\u8217\'3fs expert has not had the opportunity to address the patient-only theory of direct infringement, since that theory raises only an issue of law. 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
As Alvogen points out, however, there are important factual components to that theory that Alvogen might well have wanted its expert to address, such as whether the patient ever sets the dose amount when taking a drug such as extended release hydrocodone and whether Alvogen\u8217\'3fs Draft Label for its proposed ANDA product encourages the patient\u8212\'3fas opposed to the physician\u8212\'3fto carry out the dosing step of the asserted claims.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The need for additional discovery, including in all likelihood a supplemental report from Alvogen\u8217\'3fs infringement expert, would be burdensome to Alvogen and would potentially disrupt the trial schedule. While Alvogen could likely do the work necessary to prepare a supplemental report and conduct whatever further investigation and discovery would be necessary to prepare for the patient-only theory of direct infringement, it would be able to do so only by diverting resources from trial preparation at a critical point in the pretrial process. The Court accordingly finds that allowing Pernix to raise the patient-only theory belatedly would be prejudicial to Alvogen, would potentially disrupt the trial, and would be curable, if at all, only through the expenditure of time and resources by Alvogen that it should not have to bear at this point in the process. While the Court does not find bad faith or willful disregard of a court order by Pernix, the Court nonetheless regards the balance of factors as favoring Alvogen, particularly in light of the fact that Pernix will still be able to press its joint direct infringement theory, which has been its main theory of liability on claims 1\u8211\'3f4 and 11 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038345875&pubNum=0004074&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=PA&docFamilyGuid=I0828fca0db3d11e58e7d9ad815219c93&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f760 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 since the outset of the case.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_7_53}{\*\bkmkend co_pp_sp_999_7_53}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*7
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Alvogen\u8217\'3fs motion to strike Pernix\u8217\'3fs late-disclosed patient-only infringement theory as to infringement of claims 1\u8211\'3f4 and 11 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038345875&pubNum=0004074&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=PA&docFamilyGuid=I0828fca0db3d11e58e7d9ad815219c93&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f760 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Dkt. No. 125, is therefore GRANTED.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ib60fcbe1a3fe11e99db4e63a0d33c}{\*\bkmkend co_anchor_Ib60fcbe1a3fe11e99db4e63a0d33c}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
II. Pernix\u8217\'3fs Motion for Summary Judgment of Infringement
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Pernix has moved for summary judgment of infringement on both the first and second sets of claims that are at issue in this case. Dkt. No. 118. Pernix argues that Alvogen is liable for infringement under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=SP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_9e660000185f2" }{\fldrslt 
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. \u167\'3f 271(e)(2)(A)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 on the ground that Alvogen has submitted an application to the FDA for a drug the use of which is claimed in a patent.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In order to prove that Alvogen will be liable for induced infringement, Pernix must show that Alvogen will induce a party or parties to directly infringe the asserted claims. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033496706&pubNum=0000708&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_708_2117&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2117" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Limelight Networks, Inc. v. Akamai Techs., Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 134 S. Ct. 2111, 2117 (2014)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2044320422&pubNum=0000506&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Vanda Pharm. Inc. v. West\u8211\'3fWard Pharm. Int\u8217\'3fl Ltd.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 887 F.3d 1117 (Fed. Cir. 2018)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. To make that showing, Pernix must prove that Alvogen will possess \u8220\'3fspecific intent to encourage another\u8217\'3fs infringement and not merely that the defendant [will have] knowledge of the acts alleged to constitute infringement.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2044320422&pubNum=0000506&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_506_1129&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1129" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Vanda
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 887 F.3d at 1129
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2010878868&pubNum=0000506&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_506_1306&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1306" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
DSU Med. Corp. v. JMS Co.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 471 F.3d 1293, 1306 (Fed. Cir. 2006)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (en banc in relevant part) ).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In order to prove the direct infringement of a method claim that is a necessary component of an inducement case, the plaintiff must show that all steps of the claimed method have been (or, in the Hatch\u8211\'3fWaxman context, will be) performed by or attributable to a single entity. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2036871663&pubNum=0000506&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_506_1022&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1022" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Akamai Techs., Inc. v. Limelight Networks, Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 797 F.3d 1020, 1022 (Fed. Cir. 2015)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (en banc). Where no single actor performs all the steps of a method claim, joint direct infringement occurs if \u8220\'3fthe acts of one are attributable to the other such that a single entity is responsible for the infringement.\u8221\'3f
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2040743290&pubNum=0000506&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_506_1364&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1364" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Eli Lilly & Co. v. Teva Parenteral Meds., Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 845 F.3d 1357, 1364 (Fed. Cir. 2017)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2036871663&pubNum=0000506&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_506_1022&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1022" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Akamai
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 797 F.3d at 1022
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
). In that setting, the plaintiff must show either that the parties are (or will be) engaged in a joint enterprise or that one party directed and controlled the infringing activity of the other (or will do so). 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 To show that one party directed and controlled the infringing activity of another, the plaintiff must prove that the alleged infringer \u8220\'3fconditions participation in an activity or receipt of a benefit upon performance of a step or steps of a patented method and establishes the manner or timing of that performance.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2036871663&pubNum=0000506&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_506_1023&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1023" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Akamai
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 797 F.3d at 1023
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
As to the first two sets of claims (claims 1\u8211\'3f4 and 11 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038345875&pubNum=0004074&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=PA&docFamilyGuid=I0828fca0db3d11e58e7d9ad815219c93&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f760 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
), Pernix argues that Alvogen\u8217\'3fs application will result in infringement based on the following analysis: First, Pernix argues that there is no genuine dispute that patients and physicians will act as a single entity in directly infringing those claims.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00012044540857_ID0EYPAG_53}{\*\bkmkend co_fnRef_B00012044540857_ID0EYPAG_53}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00012044540857_53" }{\fldrslt 
{\super \b0 \cf23 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
1
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Second, Pernix argues that Alvogen will be liable for induced infringement because, if the ANDA product becomes commercially available, Alvogen will induce patients and physicians to engage in direct infringement, with the specific intent to do so. As to the final set of claims (claims 12, 17, and 19 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038345875&pubNum=0004074&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=PA&docFamilyGuid=I0828fca0db3d11e58e7d9ad815219c93&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f760 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and claim 1 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038908796&pubNum=0004074&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=PA&docFamilyGuid=I994d8600212511e6a515da1203855afb&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f499 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
), Pernix argues that there is no genuine dispute that (1) patients will directly infringe those claims when they self-administer the drug; and (2) Alvogen will induce the patients to infringe those claims with the specific intent to do so.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ib6130031a3fe11e99db4e63a0d33c}{\*\bkmkend co_anchor_Ib6130031a3fe11e99db4e63a0d33c}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
A. Claims 1\u8211\'3f4 and 11 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038345875&pubNum=0004074&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=PA&docFamilyGuid=I0828fca0db3d11e58e7d9ad815219c93&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f760 Patent
}}}
\sa200 
\sb400 
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ib6130031a3fe11e99db4e63a0d33c}{\*\bkmkend co_anchor_Ib6130031a3fe11e99db4e63a0d33c}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
1. Joint Direct Infringement
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_8_53}{\*\bkmkend co_pp_sp_999_8_53}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*8
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 In the case of the relationship between a physician and a patient, joint direct infringement of a claimed method occurs if the physician \u8220\'3fdirects or controls\u8221\'3f the patient so that the patient\u8217\'3fs acts are attributable to the physician. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2040743290&pubNum=0000506&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_506_1364&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1364" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Eli Lilly
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 845 F.3d at 1364
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The Federal Circuit explained in 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Eli Lilly & Co. v. Parenteral Medicines, Inc.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, that the requisite degree of direction and control occurs if the physician \u8220\'3fconditions participation in an activity or receipt of a benefit\u8221\'3f on the patient\u8217\'3fs performance of one or more steps of the claimed method, and the physician \u8220\'3festablishes the manner or timing of that performance.\u8221\'3f 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (emphasis omitted) (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2036871663&pubNum=0000506&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_506_1023&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1023" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Akamai
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 797 F.3d at 1023
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Pernix\u8217\'3fs theory of joint direct infringement is based on the assertion that the prescribing physician will direct and control the patient\u8217\'3fs self-administration of the accused product. The showing of joint direct infringement is made more difficult in a typical Hatch\u8211\'3fWaxman Act case such as this one, where the ANDA product is not yet on the market and where the determination of joint direct infringement is necessarily predicated not on the past conduct of physicians and patients, but on whether physicians are likely to direct patients to engage in infringing conduct and whether the physicians\u8217\'3f directions to the patients are sufficient to direct or control the patients\u8217\'3f infringing conduct.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Pernix argues that there is no disputed factual question regarding the physician\u8217\'3fs control and direction of the infringing actions of a patient when the physician prescribes an unadjusted starting dose of Alvogen\u8217\'3fs 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3bd96eea475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hydrocodone
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 extended release composition to a patient with mild or moderate 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. As support for that contention, Pernix relies on the proposed label for Alvogen\u8217\'3fs ANDA product (\u8220\'3fAlvogen\u8217\'3fs Label\u8221\'3f); on testimony from Alvogen\u8217\'3fs infringement expert; and on consent forms that are used in some instances to ensure that patients will administer opioid medications as prescribed. 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Dkt. No. 120, at 13\u8211\'3f15.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Pernix points out that Alvogen\u8217\'3fs Label directs physicians to \u8220\'3f[i]nstruct patients how to properly take Hydrocodone Bitartrate Extended Release Capsules.\u8221\'3f Dkt. No. 121\u8211\'3f1, Ex. C, at Alvhydro\u8211\'3fPTX00013463. The Label also directs patients, when taking the capsules, to \u8220\'3f[t]ake 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3bd96eea475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Hydrocodone
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Bitartrate Extended Release Capsules exactly as prescribed by your healthcare provider.\u8221\'3f 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at Alvhydro\u8211\'3fPTX00013465.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Pernix also notes that Alvogen\u8217\'3fs infringement expert, Dr. Candiotti, testified that physicians \u8220\'3fgive instruction and guidance as to when to take the medication and how to take it.\u8221\'3f Dkt. No. 121\u8211\'3f1, Ex. F, at 158:15\u8211\'3f17. Dr. Candiotti further acknowledged that some physicians use a consent form when prescribing opioid drugs. On one such form, offered as evidence in support of Pernix\u8217\'3fs motion, the patient is asked to state \u8220\'3fI will take these medications only as prescribed and will not change the amount or dosing frequency without authorization from my physician,\u8221\'3f and that \u8220\'3fI understand and agree that failure to adhere to these policies will be considered noncompliance and my result in the cessation of opioid prescribing by my physician and possible dismissal from this clinic.\u8221\'3f 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 139:15\u8211\'3f141:13.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In its response, Alvogen argues that Pernix\u8217\'3fs evidence does not show that physicians will necessarily control and direct patients in taking the extended release 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3bd96eea475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hydrocodone
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 composition because there is no evidence that physicians will \u8220\'3fcondition\u8221\'3f continued treatment on the patient\u8217\'3fs administering Alvogen\u8217\'3fs ANDA product as prescribed. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2036871663&pubNum=0000506&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_506_1023&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1023" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Akamai
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 797 F.3d at 1023
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. In addition, Alvogen argues that physicians typically have no means of verifying that patients are adhering to the physicians\u8217\'3f directives regarding patient adherence to the prescribing directions. Dkt. No. 143, at 9\u8211\'3f13.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_9_53}{\*\bkmkend co_pp_sp_999_9_53}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*9
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Although it is clear that a physician gives instructions to a patient as to dosing levels and practices, the extent to which those instructions constitute \u8220\'3fdirection and control\u8221\'3f of the patient\u8217\'3fs infringing conduct turns on factual questions such as whether the physician conditions receipt of a benefit\u8212\'3fcontinued treatment for chronic pain\u8212\'3fon the patient\u8217\'3fs performance of the administering step, i.e., administering the drug as prescribed. In support of its assertion that the facts are undisputed on that issue, Pernix cites the fact that because 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3bd96eea475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hydrocodone
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is a controlled substance, physicians enter into agreements with their patients requiring the patients to take the drug as prescribed by the physician, and thus exercise control and direction over the patient\u8217\'3fs conduct in that regard. In addition, relying on the deposition testimony of Alvogen\u8217\'3fs infringement expert, Pernix argues that physicians establish the timing and manner in which the patients administer the drug.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
While Pernix\u8217\'3fs evidence could support a finding that physicians exercise direction and control over the self-administration of hydrocodone extended release formulations by patients, the evidence on that issue is not so compelling as to justify the entry of summary judgment in Pernix\u8217\'3fs favor. Rather, the Court concludes that the issue turns on disputed facts, the resolution of which must await trial.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ib618cc95a3fe11e99db4e63a0d33c}{\*\bkmkend co_anchor_Ib618cc95a3fe11e99db4e63a0d33c}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ib618cc95a3fe11e99db4e63a0d33c}{\*\bkmkend co_anchor_Ib618cc95a3fe11e99db4e63a0d33c}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
2. Inducement of Infringement by Alvogen\u8217\'3fs Label
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Because Pernix\u8217\'3fs theory of liability for Alvogen on all of the asserted claims depends on inducement of infringement, Pernix must prove not only the elements of direct infringement, but also the elements of inducement. Proof of induced infringement, for claims 1\u8211\'3f4 and 11 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038345875&pubNum=0004074&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=PA&docFamilyGuid=I0828fca0db3d11e58e7d9ad815219c93&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f760 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, requires Pernix to show that Alvogen\u8217\'3fs actions will induce joint direct infringement by physicians and patients and that Alvogen will engage in those actions with the specific intent to do so. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2040743290&pubNum=0000506&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_506_1368&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1368" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Eli Lilly
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 845 F.3d at 1368
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2036222044&pubNum=0000506&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_506_631&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_631" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Takeda Pharm. USA, Inc. v. West\u8211\'3fWard Pharm. Corp.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 785 F.3d 625, 631 (Fed. Cir. 2015)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. In the context of patent infringement litigation involving pharmaceuticals, the Federal Circuit has held that \u8220\'3fthe sale of a product specifically labeled for use in a patented method constitutes inducement to infringe that patent.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2025797503&pubNum=0006538&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_6538_926&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_6538_926" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Eli Lilly & Co. v. Actavis Elizabeth LLC
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 435 Fed.Appx. 917, 926 (Fed. Cir. 2011)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In a Hatch\u8211\'3fWaxman Act case where the act of infringement under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=SP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_9e660000185f2" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
section 271(e)(2)(A)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 consists of the filing of an ANDA for a method of treatment protected by a patent, \u8220\'3f[t]he pertinent question is whether the proposed label [of the ANDA product] instructs users to perform the patented method.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2023571452&pubNum=0000506&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_506_1060&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1060" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
AstraZeneca LP v. Apotex, Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 633 F.3d 1042, 1060 (Fed. Cir. 2010)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. In that setting, the Federal Circuit has explained, \u8220\'3f[t]he label must encourage, recommend, or promote infringement.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2036222044&pubNum=0000506&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_506_631&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_631" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Takeda
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 785 F.3d at 631
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Evidence that a proposed label will \u8220\'3finevitably lead some consumers to practice the claimed method\u8221\'3f can suffice to support a finding of specific intent to induce infringement. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2023571452&pubNum=0000506&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_506_1060&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1060" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
AstraZeneca
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 633 F.3d at 1060
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2041396636&pubNum=0007903&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_7903_585&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_7903_585" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Novartis Pharm. Corp. v. Breckenridge Pharm., Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 248 F. Supp. 3d 578, 585 (D. Del. 2017)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Put another way, the question is whether the instructions in the label \u8220\'3fteach an infringing use ... such that we are willing to infer from those instructions an affirmative intent to infringe the patent.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2036222044&pubNum=0000506&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_506_631&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_631" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Takeda
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 785 F.3d at 631
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (emphasis omitted); 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2043570962&pubNum=0000999&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Rhodes Pharm. L.P. v. Indivior, Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, No. 16\u8211\'3fcv\u8211\'3f1308, 2018 WL 326405, at *7 (D. Del. Jan. 8, 2018)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Pernix relies on Alvogen\u8217\'3fs Label and testimony by Alvogen\u8217\'3fs expert, Dr. Candiotti, to support its contention that there is no disputed question of fact regarding the issue of inducement. Pernix quotes the Alvogen Label, which states: \u8220\'3fNo adjustment in starting dose ... is required in patients with mild or moderate 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.\u8221\'3f Dkt. No. 121\u8211\'3f1, Ex. C, at Alvhydro\u8211\'3fPTX00013439, 13445, 13455. The label further directs the patient as follows: \u8220\'3fTake ... exactly as prescribed by your healthcare provider.\u8221\'3f 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at Alvhydro\u8211\'3fPTX00013465. And Pernix cites Alvogen\u8217\'3fs expert, who testified that the Alvogen Label constitutes a \u8220\'3fdosing recommendation\u8221\'3f that \u8220\'3ftells you how to dose\u8221\'3f Alvogen\u8217\'3fs ANDA product in patients with mild or moderate 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Ex. F, at 174:4\u8211\'3f9.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_10_53}{\*\bkmkend co_pp_sp_999_10_53}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*10
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 For its part, Alvogen argues that its Label does not encourage, recommend, or promote administering Alvogen\u8217\'3fs ANDA product to parties with mild or moderate 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, nor does it encourage prescribing the ANDA product to patients with mild or moderate 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 without adjusting the starting dose relative to the dosage prescribed to a normal patient. Inferring specific intent to induce infringement from a pharmaceutical label, Alvogen argues, requires recommending, encouraging, or promoting an infringing use, not merely describing an infringing mode as a possible alternative. Alvogen contends that the portions of its Label to which Pernix points merely describe the effects of Alvogen\u8217\'3fs ANDA product on patients with mild or moderate 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and do not do not encourage, recommend, or promote the use of the claimed methods in treating such patients.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Alvogen distinguishes the 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Eli Lilly
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 case on which Pernix relies on the ground that in that case the ANDA label 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8220\'3fprovided direct and fervent instructions for patients to perform the claim step of administering 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I0b3846ec0ccd11deb055de4196f001f3&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
folic acid
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
,\u8221\'3f Dkt. No. 143, at 18, which was essential to the safe use of the chemotherapy procedure in which the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I0b3846ec0ccd11deb055de4196f001f3&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
folic acid
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 was involved. By contrast, Alvogen argues, Alvogen\u8217\'3fs label merely \u8220\'3fdescribes\u8221\'3f the use of the product in patients with 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, and therefore does not reflect \u8220\'3fan affirmative intent to infringe the patent.\u8221\'3f 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2040743290&pubNum=0000506&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_506_1368&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1368" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Eli Lilly
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 845 F.3d at 1368
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
). Nor, according to Alvogen, does the Alvogen label recommend, promote, or encourage the non-adjustment of the starting dose for patients with 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Alvogen contends that the label merely \u8220\'3finforms physicians that they may or may not adjust the starting dose in patients with mild or moderate 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.\u8221\'3f 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 19.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The Court concludes that this issue presents an issue of fact for trial and cannot be resolved on summary judgment. Alvogen\u8217\'3fs expert testified that the Alvogen Label gives \u8220\'3finstruction and guidance\u8221\'3f as to the dosing for patients with 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, but stopped short of saying that the Label would give directions to the physician. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Dkt. No. 121\u8211\'3f1, Ex. F, at 172:6\u8211\'3f19. In the absence of more unequivocal evidence on the issue of specific intent and inducement, the Court regards the matter as inappropriate for summary judgment.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ib61e23c1a3fe11e99db4e63a0d33c}{\*\bkmkend co_anchor_Ib61e23c1a3fe11e99db4e63a0d33c}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
B. Claims 12, 17, and 19 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038345875&pubNum=0004074&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=PA&docFamilyGuid=I0828fca0db3d11e58e7d9ad815219c93&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f760 Patent
}}}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
 and Claim 1 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038908796&pubNum=0004074&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=PA&docFamilyGuid=I994d8600212511e6a515da1203855afb&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f499 Patent
}}}
\sa200 
\sb400 
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In order to prove that Alvogen\u8217\'3fs ANDA product will infringe claims 12, 17, and 19 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038345875&pubNum=0004074&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=PA&docFamilyGuid=I0828fca0db3d11e58e7d9ad815219c93&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f760 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and claim 1 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038908796&pubNum=0004074&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=PA&docFamilyGuid=I994d8600212511e6a515da1203855afb&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f499 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Pernix must show that Alvogen will induce infringement by patients with mild or moderate 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 to administer an extended release 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3bd96eea475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hydrocodone
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 formulation having a release profile that satisfies the release profile limitations of those claims. Unlike for claims 1\u8211\'3f4 and 11 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038345875&pubNum=0004074&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=PA&docFamilyGuid=I0828fca0db3d11e58e7d9ad815219c93&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f760 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Pernix is not required to show joint direct infringement by the patient and a physician, but only need prove inducement of direct infringement by the patient.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Moreover, the proof of inducement required to show induced infringement of claims 12, 17, and 19 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038345875&pubNum=0004074&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=PA&docFamilyGuid=I0828fca0db3d11e58e7d9ad815219c93&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f760 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and claim 1 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038908796&pubNum=0004074&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=PA&docFamilyGuid=I994d8600212511e6a515da1203855afb&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f499 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is less demanding than the proof required to show induced infringement of claims 1\u8211\'3f4 and 11 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038345875&pubNum=0004074&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=PA&docFamilyGuid=I0828fca0db3d11e58e7d9ad815219c93&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f760 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. While claims 1\u8211\'3f4 and 11 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038345875&pubNum=0004074&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=PA&docFamilyGuid=I0828fca0db3d11e58e7d9ad815219c93&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f760 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 require proof that Alvogen\u8217\'3fs Label induces physicians to direct and patients to administer an unadjusted starting dose of an extended release formulation of hydrocodone, claims 12, 17, and 19 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038345875&pubNum=0004074&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=PA&docFamilyGuid=I0828fca0db3d11e58e7d9ad815219c93&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f760 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and claim 1 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038908796&pubNum=0004074&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=PA&docFamilyGuid=I994d8600212511e6a515da1203855afb&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f499 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 do not require a showing of inducement to administer an unadjusted starting dose. Instead, the latter claims only require inducement to treat pain in a patient with mild or moderate 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 by administering an oral dosage unit having 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3bd96eea475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hydrocodone
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 bitartrate as the only active ingredient, where the dosage unit results in a particular pharmacokinetic release profile in the relevant patient population.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_11_53}{\*\bkmkend co_pp_sp_999_11_53}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*11
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Nonetheless, Pernix must demonstrate that Alvogen\u8217\'3fs Label will induce hepatically impaired patients to use Alvogen\u8217\'3fs ANDA product for the treatment of pain. That issue raises a question of fact: whether the Alvogen Label would encourage a patient with mild or moderate 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 to use Alvogen\u8217\'3fs ANDA product to inhibit pain.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In an effort to show that the factual issue of inducement could not reasonably be decided in Alvogen\u8217\'3fs favor, Pernix cites portions of Alvogen\u8217\'3fs Label as well as excerpts from the report and deposition of Alvogen\u8217\'3fs infringement expert, Dr. Candiotti. 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In particular, Pernix contrasts the portions of Alvogen\u8217\'3fs Label that refer to patients with mild or moderate 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 with the portions addressing severe impairment. The \u8220\'3fDosage and Administration\u8221\'3f section of the Label provides, in pertinent part, as follows: \u8220\'3fPatients with Severe 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Hepatic Impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
: Initiate dosing with 10 mg every 12 hours and titrate carefully, while monitoring for 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic33f44b7475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
respiratory depression
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. No adjustment in starting dose with 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3bd96eea475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Hydrocodone
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Bitartrate Extended Release Capsules is required in patients with mild or moderate 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.\u8221\'3f Dkt. No. 121\u8211\'3f1, Ex. C, at Alvhydro\u8211\'3fPTX00013439.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Similarly, a section of the Label entitled \u8220\'3fDosage Modification in Patients with Severe 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Hepatic Impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
,\u8221\'3f provides: \u8220\'3fPatients with severe 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 may have higher plasma concentrations of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3bd96eea475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hydrocodone
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 than those with normal function. Therefore, initiate therapy with 10 mg every 12 hours and titrate carefully, while monitoring for 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic33f44b7475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
respiratory depression
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, sedation, and hypotension. No adjustment in starting dose with 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3bd96eea475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Hydrocodone
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Bitartrate Extended Release Capsules is required in patients with mild or moderate 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.\u8221\'3f 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at Alvhydro\u8211\'3fPTX00013445. Finally, a section of the Label entitled \u8220\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Hepatic Impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8221\'3f provides: \u8220\'3fNo adjustment in starting dose with 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3bd96eea475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Hydrocodone
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Bitartrate Extended Release Capsules is required in patients with mild or moderate 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Patients with severe 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 may have higher plasma concentrations than those with normal hepatic function .... Therefore, a dosage reduction is recommended for patients with severe 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 .... Monitor patients with severe 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 closely for 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic33f44b7475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
respiratory depression
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, sedation and hypotension ....\u8221\'3f 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at Alvhydro\u8211\'3fPTX00013455.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Pernix also relies on the general statement in the \u8220\'3fMedication Guide\u8221\'3f section of Alvogen\u8217\'3fs Label that directs patients as follows: \u8220\'3fDo not change your dose. Take 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3bd96eea475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Hydrocodone
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Bitartrate Extended Release Capsules exactly as prescribed by your healthcare provider.\u8221\'3f 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at Alvhydro\u8211\'3fPTX00013465. To the same effect, Pernix notes that Dr. Candiotti admitted that the medication guides in Alvogen\u8217\'3fs Label are Alvogen\u8217\'3fs \u8220\'3finstructions to the patient,\u8221\'3f in which Alvogen \u8220\'3fis saying, \u8216\'3fDo not change your dose. Take the medication exactly as prescribed by your health care provider.\u8217\'3f \u8221\'3f Dkt. 121\u8211\'3f1, Ex. F, at 71:17\u8211\'3f72:7. Dr. Candiotti acknowledged that the Label gives \u8220\'3fdirection to not change your dose and to take the pills exactly as prescribed.\u8221\'3f 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 146:5\u8211\'3f6.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Alvogen argues that Pernix\u8217\'3fs evidence does not justify entry of an order of summary judgment on claims 12, 17, and 19 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038345875&pubNum=0004074&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=PA&docFamilyGuid=I0828fca0db3d11e58e7d9ad815219c93&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f760 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and claim 1 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038908796&pubNum=0004074&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=PA&docFamilyGuid=I994d8600212511e6a515da1203855afb&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f499 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. With respect to the references to 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 in Alvogen\u8217\'3fs Label, Alvogen points out that the Label contains explicit directions for patients with severe 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (e.g., \u8220\'3fInitiate dosing with 10 mg every 12 hours and titrate carefully, while monitoring for 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic33f44b7475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
respiratory depression
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.\u8221\'3f), but does not use directory language when referring to patients with mild or moderate 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (e.g., \u8220\'3fNo adjustment in starting dose with 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3bd96eea475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Hydrocodone
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Bitartrate Extended Release Capsules is required in patients with mild or moderate 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.\u8221\'3f). With respect to Dr. Candiotti\u8217\'3fs testimony and the Medication Guide in Alvogen\u8217\'3fs Label, Alvogen explains that the statements on which Pernix relies simply advise the patient to comply with the prescribing physician\u8217\'3fs directions, which does not constitute direct evidence of an intent by Alvogen to induce hepatically impaired patients to use Alvogen\u8217\'3fs ANDA product.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_12_53}{\*\bkmkend co_pp_sp_999_12_53}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*12
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Alvogen contends that, at most, its Label and Dr. Candiotti\u8217\'3fs testimony indicate that Alvogen has not affirmatively sought to 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
discourage
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 such patients from using its ANDA product. Thus, rather than demonstrating intentional inducement, Alvogen argues that the statements in its Label on which Pernix relies merely describe an infringing mode without \u8220\'3frecommending, encouraging, or promoting an infringing use, or suggesting that an infringing use should be performed.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2036222044&pubNum=0000506&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_506_631&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_631" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Takeda
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 785 F.3d at 631
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (citations, quotation marks, and alterations omitted).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Finally, citing 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2003082816&pubNum=0000506&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_506_1365&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1365" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Warner\u8211\'3fLambert Co. v. Apotex Corp.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 316 F.3d 1348, 1365 (Fed. Cir. 2003)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2019816886&pubNum=0000506&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_506_1329&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1329" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Vita\u8211\'3fMix Corp. v. Basic Holding, Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 581 F.3d 1317, 1329 (Fed. Cir. 2009)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Alvogen notes that where, as here, a product has substantial non-infringing uses, intent to induce infringement cannot be inferred simply because the defendant is aware that some users of its product may be infringing the patent. Instead, in such a case, the plaintiff must \u8220\'3fshow[ ] statements or actions directed to promoting infringement.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2023571452&pubNum=0000506&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_506_1059&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1059" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
AstraZeneca
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 633 F.3d at 1059
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2017707960&pubNum=0000506&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_506_1341&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1341" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Ricoh Co. v. Quanta Computer Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 550 F.3d 1325, 1341 (Fed. Cir. 2008)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 ).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
As noted, the question whether the evidence of particular statements by an accused infringer evinces a specific intent to induce infringement is a question of fact. And on that factual issue, the reports of Pernix\u8217\'3fs expert, Dr. Gudin, and Alvogen\u8217\'3fs expert, Dr. Candiotti, are in conflict. Dr. Gudin states that in his view Alvogen\u8217\'3fs Label provides instructions to physicians regarding the use of Alvogen\u8217\'3fs ANDA product in the treatment of patients with mild or moderate 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Dkt. No. 144\u8211\'3f2, \u182\'3f\u182\'3f 50\u8211\'3f53. Dr. Candiotti, by contrast, views the pertinent portions of Alvogen\u8217\'3fs Label as not promoting, encouraging, or recommending that physicians prescribe Alvogen\u8217\'3fs ANDA product for patients with mild or moderate 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, but as merely responding to the FDA\u8217\'3fs guidance requiring a drug manufacturer to conduct a 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 study, and to report the results of that study on its label when hepatic metabolism has a substantial role in the elimination of the drug from the body. Dkt. No. 121\u8211\'3f1, Ex. E, \u182\'3f\u182\'3f 67\u8211\'3f68.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Given the conflict between the views taken by the two experts, the Court concludes that the inducement issue presents a disputed issue of fact. While a factual question can be resolved on summary judgment if a reasonable finder of fact could reach only one conclusion as to that question, the Court does not regard the evidence offered at this juncture as compelling such a conclusion on the issue of inducement as to claims 12, 17, and 19 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038345875&pubNum=0004074&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=PA&docFamilyGuid=I0828fca0db3d11e58e7d9ad815219c93&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f760 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and claim 1 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038908796&pubNum=0004074&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=PA&docFamilyGuid=I994d8600212511e6a515da1203855afb&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f499 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Moreover, the Court notes that the inducement question turns on an issue of specific intent and \u8220\'3f[t]he issue of intent is particularly inappropriate for resolution by summary judgment because evaluating state of mind often requires the drawing of inferences from the conduct of parties about which reasonable persons might differ.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2004631839&pubNum=0000506&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_506_524&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_524" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Justofin v. Metro. Life Ins. Co.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 372 F.3d 517, 524 (3d Cir. 2004)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (quotation marks omitted); 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
see also
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2043134164&pubNum=0000506&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_506_644&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_644" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Sanofi v. Watson Labs. Inc.
}
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
, 875 F.3d 636, 644 (Fed. Cir. 2017)
}
}}}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
 (stating, regarding induced infringement in a Hatch\u8211\'3fWaxman Act case, that \u8220\'3fintent is a factual determination that may rest on circumstantial evidence\u8221\'3f); 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2044354440&pubNum=0000999&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Impax Labs., Inc. v. Actavis Labs. FL, Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, No. 15\u8211\'3fcv\u8211\'3f6934, 2018 WL 1863826, at *13 (D.N.J. Apr. 18, 2018)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (same). Resolution of this issue will therefore have to await trial.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00022044540857_ID0ESEAI_53}{\*\bkmkend co_fnRef_B00022044540857_ID0ESEAI_53}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00022044540857_53" }{\fldrslt 
{\super \b0 \cf23 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
2
}}}
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_13_53}{\*\bkmkend co_pp_sp_999_13_53}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*13
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Accordingly, Pernix\u8217\'3fs motion for summary judgment of infringement with respect to each of the asserted claims, Dkt. No. 118, is therefore DENIED.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ib627c0b1a3fe11e99db4e63a0d33c}{\*\bkmkend co_anchor_Ib627c0b1a3fe11e99db4e63a0d33c}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
III. Alvogen\u8217\'3fs Motion for Summary Judgment of Anticipation
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Alvogen has moved for summary judgment of invalidity for anticipation under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS102&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. \u167\'3f 102
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. In its motion, Alvogen relies on two prior art references, U.S. Patent Appl. No. 2006/0240105 (\u8220\'3fDevane\u8221\'3f) and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034164321&pubNum=0004074&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=PA&docFamilyGuid=Ie1678810287911e4bfee9033844a2ace&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
U.S. Patent No. 8,808,740 (\u8220\'3fHuang\u8221\'3f)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ib62835e1a3fe11e99db4e63a0d33c}{\*\bkmkend co_anchor_Ib62835e1a3fe11e99db4e63a0d33c}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
A. Huang as Prior Art
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The parties dispute whether Huang is prior art. In addition to raising that issue in its opposition to Alvogen\u8217\'3fs motion, Dkt. No. 141, at 27\u8211\'3f28, Pernix has filed a motion in limine to preclude Alvogen from relying on Huang as prior art, Dkt. No. 137, and it has sought to exclude the testimony of one of Alvogen\u8217\'3fs experts on the ground that his opinion cites Huang as prior art, Dkt. No. 135, at 5\u8211\'3f7. The Court concludes that factual disputes preclude a determination as a matter of law whether Huang is prior art. The Court therefore will not enter summary judgment of invalidity based on Huang.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00032044540857_ID0EDIAI_53}{\*\bkmkend co_fnRef_B00032044540857_ID0EDIAI_53}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00032044540857_53" }{\fldrslt 
{\super \b0 \cf23 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
3
}}}
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The patents-in-suit claim priority to, 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
inter alia
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, U.S. Provisional Appl. No. 61/677,601, which was filed on July 31, 2012. The application for the Huang patent was filed on December 21, 2011. Because Huang predates the filing date of the provisional application for the patents in suit, Huang qualifies as prior art unless Pernix can show that the patents in suit are entitled to an earlier priority date. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2001797960&pubNum=0000506&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_506_1361&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1361" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Loral Fairchild Corp. v. Matsushita Elec. Indus. Co.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 266 F.3d 1358, 1361 (Fed. Cir. 2001)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3f[The patentee] bear[s] a burden of production to present evidence of its asserted actual reduction to practice prior to the filing date of its patent application.\u8221\'3f).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In an effort to establish a priority date before the filing date for the Huang application, Pernix argues that the inventors of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038345875&pubNum=0004074&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=PA&docFamilyGuid=I0828fca0db3d11e58e7d9ad815219c93&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f760
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038908796&pubNum=0004074&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=PA&docFamilyGuid=I994d8600212511e6a515da1203855afb&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f499 patents
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 reduced the inventions of those patents to practice no later than November 2, 2011.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00042044540857_ID0EELAI_53}{\*\bkmkend co_fnRef_B00042044540857_ID0EELAI_53}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00042044540857_53" }{\fldrslt 
{\super \b0 \cf23 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
4
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Dkt. No. 137, at 4\u8211\'3f5. Specifically, Pernix relies on a draft of a clinical study report, dated November 2, 2011. That report included the results of testing that compared the pharmacokinetic profile of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3bd96eea475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hydrocodone
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 in normal individuals and in individuals suffering from mild or moderate 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Dkt. No. 138\u8211\'3f1, Ex. E, at 178. The draft report concluded that \u8220\'3fsubjects with mild or moderate 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 are likely to experience slightly higher 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3bd96eea475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hydrocodone
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 exposure after administration of HC\u8211\'3fCR, compared to subjects with no 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Overall, the increase in exposure is likely to be modest and would not warrant a priori dose adjustment in these populations.\u8221\'3f 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 117\u8211\'3f18. The study described in the draft report was performed using \u8220\'3fHC\u8211\'3fCR 20 mg,\u8221\'3f 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 117, which Pernix has confirmed was an extended release hydrocodone formulation that was previously disclosed in the prior art Devane application, 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
see
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Dkt. No. 163\u8211\'3f3, at 3\u8211\'3f8.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_14_53}{\*\bkmkend co_pp_sp_999_14_53}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*14
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 In support of its argument that the inventors reduced their invention to practice by November 2, 2011, Pernix points to deposition testimony from two of the three inventors of the patents-in-suit. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Dkt. No. 138\u8211\'3f1, Ex. G, at 142:13\u8211\'3f148:21 (deposition of inventor Andrew Hartman, testifying that the invention of \u8220\'3fusing a controlled release formulation of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3bd96eea475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hydrocodone
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 in which no adjustment to starting dose would be necessary for patients with mild or moderate 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8221\'3f was discovered \u8220\'3fmid to late summer\u8221\'3f of 2011, before the November 17, 2011 date of the final clinical study report); 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Dkt. No. 138\u8211\'3f1, Ex. F, at 112:22\u8211\'3f120:13 (deposition of inventor Christopher M. Rubino, discussing the draft study in general terms).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Reduction to practice is a legal issue based on underlying factual determinations. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1997222583&pubNum=0000506&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_506_592&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_592" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Estee Lauder Inc. v. L\u8217\'3fOreal, S.A.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 129 F.3d 588, 592 (Fed. Cir. 1997)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. \u8220\'3fTo demonstrate an actual reduction to practice, the [patentee] must have: (1) constructed an embodiment or performed a process that met all the limitations of the claim and (2) determined that the invention would work for its intended purpose.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2043470481&pubNum=0006538&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_6538_1002&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_6538_1002" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Nintendo of Am. Inc. v. iLife Techs., Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 717 Fed.Appx. 996, 1002 (Fed. Cir. 2017)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2037281764&pubNum=0000506&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_506_1318&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1318" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
In re Steed
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 802 F.3d 1311, 1318 (Fed. Cir. 2015)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 ); 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
see also
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1997222583&pubNum=0000506&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_506_593&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_593" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Estee Lauder
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 129 F.3d at 593
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fIt is well-settled that conception and reduction to practice cannot be established nunc pro tunc. There must be 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
contemporaneous recognition and appreciation
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 of the invention represented by the counts.\u8221\'3f (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1973108450&pubNum=0000350&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_350_1401&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_350_1401" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Breen v. Henshaw
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 472 F.2d 1398, 1401 (CCPA 1973)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 ) ).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Alvogen makes two arguments about why Huang is prior art to the patents-in-suit, notwithstanding Pernix\u8217\'3fs arguments about the inventors\u8217\'3f conception and reduction to practice. First, Alvogen argues that \u8220\'3fPernix\u8217\'3fs motion relies solely on the deposition testimony of one of the three named inventors, Andrew Hartman, to demonstrate that conception of the alleged invention predates Huang.\u8221\'3f Dkt. No. 164, at 3. Alvogen contends that \u8220\'3fwhen a party seeks to prove conception via the oral testimony of a putative inventor, the party must proffer evidence corroborating that testimony.\u8221\'3f 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2003117519&pubNum=0000506&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_506_1340&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1340" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Singh v. Brake
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 317 F.3d 1334, 1340\u8211\'3f41 (Fed. Cir. 2003)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 ). That argument is unpersuasive. Pernix relies not only on the testimony of Mr. Hartman, but also on the draft study and the testimony of his co-inventor, Dr. Rubino. The Federal Circuit has stated that \u8220\'3fno similar condition of \u8216\'3fcorroboration\u8217\'3f is imposed on an inventor\u8217\'3fs notebook, or indeed any documentary or physical evidence, as a condition for its serving as evidence of reduction to practice,\u8221\'3f although an \u8220\'3funwitnessed notebook is insufficient on its own to support a claim of reduction to practice.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2008351576&pubNum=0000506&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_506_1169&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1169" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Medichem, S.A. v. Rolabo, S.L.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 437 F.3d 1157, 1169 (Fed. Cir. 2006)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
see also
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fOnce properly admitted into evidence, documentary and physical evidence is assigned probative value and collectively weighted to determine whether reduction to practice has been achieved.\u8221\'3f). Alvogen has not presented any countervailing evidence that calls into question the authenticity of the draft study report or the admissibility of the inventors\u8217\'3f testimony.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Second, Alvogen argues that the inventors cannot antedate Huang unless \u8220\'3f(1) the inventors appreciated that the species they reduced to practice included or pointed to the species disclosed in the prior art reference; or (2) the prior art species would have been an obvious variant of the species reduced to practice.\u8221\'3f Dkt. No. 164, at 4 (citing 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
In re 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1965100976&pubNum=0000350&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_350_992&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_350_992" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Clarke
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 356 F.2d 987, 992\u8211\'3f93 (CCPA 1966)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 ). In 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Clarke
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, which was an appeal from an interference action before the Patent and Trademark Office (\u8220\'3fPTO\u8221\'3f), the applicant was seeking a patent on a genus of compounds and attempted to antedate an anticipatory reference that disclosed one species within that genus by demonstrating that the inventor had reduced a different species to practice.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_15_53}{\*\bkmkend co_pp_sp_999_15_53}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*15
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 The court rejected the applicant\u8217\'3fs argument. The court explained that in such a case, \u8220\'3fantedating affidavits must contain facts showing a completion of \u8216\'3fthe invention\u8217\'3f commensurate with the extent the invention is shown in the reference, whether or not it be a showing of the identical disclosure of the reference.\u8221\'3f
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1965100976&pubNum=0000350&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_350_992&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_350_992" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 992
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. That requirement was not satisfied in 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Clarke
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the court held, because there was no evidence that either a person of ordinary skill in the art or the applicant would have considered that the prior art species \u8220\'3freasonably could be expected to have properties related to that found for the [applicant\u8217\'3fs] species, such that the [prior art] species would be properly included within the invention.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1965100976&pubNum=0000350&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_350_993&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_350_993" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 993
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The court therefore could not conclude from the evidence \u8220\'3fthat so much of the invention as encompasses the referenced species was in appellant\u8217\'3fs possession, and thereby reduced to practice prior to the effective date of the reference.\u8221\'3f 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
\par 
}
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Alvogen argues that this case is identical to 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Clarke
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Alvogen contends that although the inventors discovered that Devane\u8217\'3fs formulation of extended release hydrocodone can be administered to hepatically impaired patients without adjusting the starting dose, the inventors did not appreciate, nor would it have been obvious, that the formulation disclosed in Huang would have the same property. In support of its position that the inventors did not appreciate that their discovery of the properties of the Devane formulation would apply to Huang\u8217\'3fs formulation, Alvogen cites testimony from two of the inventors that even as of the present day they do not know why Devane\u8217\'3fs formulation exhibits that unexpected result, as compared to other opioid products. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Dkt. No. 165\u8211\'3f5, at 254:20\u8211\'3f25 (deposition of Cynthia Robinson, \u8220\'3fQ: Do you know what it is about the Zohydro formulation that resulted in the surprising result? ... A: I honestly couldn\u8217\'3ft say.\u8221\'3f); Dkt. No. 165\u8211\'3f6, at 167:24\u8211\'3f168:5 (deposition of Andrew Hartman, \u8220\'3fQ: .... Why do you believe the Zohydro product performed differently, in your view, than the other products that you\u8212\'3fopioid products that you were referencing? ... [A:] I don\u8217\'3ft know the answer to that question.\u8221\'3f); Dkt. No. 136\u8211\'3f7, at 82:10\u8211\'3f13 (deposition of Brooks Boyd, Rule 30(b)(6) designee for Zogenix, Inc., Pernix\u8217\'3fs predecessor: \u8220\'3fQ: And are you aware of other\u8212\'3fany other 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3bd96eea475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hydrocodone
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 formulations that achieve the results of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 study? A: No.\u8221\'3f).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Although the 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Clarke
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 decision is a half-century old, 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Clarke
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is still good law. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1983139472&pubNum=0000350&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_350_1546&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_350_1546" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
In re Mulder
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 716 F.2d 1542, 1546 (Fed. Cir. 1983)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (discussing and distinguishing 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Clarke
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
); 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
In re 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1976123679&pubNum=0000350&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_350_512&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_350_512" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Schaub
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 537 F.2d 509, 512 (CCPA 1976)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (applying 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Clarke
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
); 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2043788247&pubNum=0000999&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Unified Patents Inc. v. Heslop
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, No. IPR2016\u8211\'3f01464, 2018 WL 801602, at *13 (PTAB Feb. 6, 2018)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (citing 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Clarke
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 in inter partes review proceeding); 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1994624601&pubNum=0000999&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
In the Matter of Certain Anti\u8211\'3fTheft Deactivatable Resonant Tags & Components Thereof
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Inv. No. 337\u8211\'3fTA\u8211\'3f347, USITC Pub. 2811, 1994 WL 931908 (Sept. 1, 1994)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (citing 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Clarke
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
). The PTO\u8217\'3fs Manual of Patent Examining Procedure (\u8220\'3fMPEP\u8221\'3f) cites 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Clarke
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and instructs as follows:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Proof of prior completion of a species different from the species of the reference or activity will be sufficient to overcome a reference indirectly under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000547&cite=37CFRS1.131&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
37 CFR 1.131(a)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 if the species shown in the reference or activity would have been obvious in view of the species shown to have been made by the applicant. Alternatively, if the applicant cannot show possession of the species of the reference or activity in this manner, the applicant may be able to antedate the reference or activity indirectly by, for example, showing prior completion of one or more species, placing applicant in possession of the claimed genus prior to the reference\u8217\'3fs or activity\u8217\'3fs date. The test is whether the species completed by applicant prior to the reference date or the activity\u8217\'3fs date provided an adequate basis for inferring that the invention has generic applicability.
\par 
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_16_53}{\*\bkmkend co_pp_sp_999_16_53}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*16
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&pubNum=1015320&cite=MPEPs715.03&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=TS&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
MPEP \u167\'3f 715.03 (9th ed., rev. Jan. 2018)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (citations omitted).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Moreover, the rationale underlying 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Clarke
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is consistent with the reasoning of more recent Federal Circuit decisions. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2012942683&pubNum=0000506&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_506_1287&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1287" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Frazer v. Schlegel
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 498 F.3d 1283, 1287 (Fed. Cir. 2007)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3f[P]riority as to a genus may be indeed shown by prior invention of a single species ... but the genus will not be patentable to an applicant unless he has generic support therefor\u8221\'3f (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1990014746&pubNum=0000350&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_350_323&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_350_323" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
In re Zletz
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 893 F.2d 319, 323 (Fed. Cir. 1989)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 ) ); 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1991039332&pubNum=0000350&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
In re Rozmus
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 928 F.2d 412, 1991 WL 17232, at *1 (Fed. Cir. 1991)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fIn order to remove a reference, a Rule 131 declaration must show that prior to the effective date of the reference the applicant had reduced to practice so much of the claimed invention as the reference shows.\u8221\'3f).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Pernix responds that 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Clarke
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is inapplicable to the facts of this case, for several reasons. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Dkt. No. 185, at 1\u8211\'3f2. First, Pernix suggests that 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Clarke
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 should be limited to the interference context and applied only to \u8220\'3fchemical Markush genus-species situations.\u8221\'3f Dkt. No. 185, at 1 (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1965100976&pubNum=0000350&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_350_990&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_350_990" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Clarke
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 356 F.2d at 990
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
). However, Pernix gives no reasoned explanation why 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Clarke
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 should be limited in that manner, nor does the Court perceive any. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
See, e.g.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032909107&pubNum=0000506&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_506_1190&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1190" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Alcon Research Ltd. v. Barr Labs., Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 745 F.3d 1180, 1190 (Fed. Cir. 2014)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (in a Hatch\u8211\'3fWaxman infringement action, applying 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1989099995&pubNum=0000350&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Newman v. Quigg
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 877 F.2d 1575 (Fed. Cir. 1989)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, a decision from an appeal from the U.S. Patent and Trademark Office).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Pernix next points to the fact that Alvogen expert Michael Mayersohn purportedly \u8220\'3fadmitted\u8221\'3f that the claims do not recite a genus. Dkt. No. 187\u8211\'3f1, at 133:24\u8211\'3f134:4 (\u8220\'3fQ. Do the asserted claims recite a genus? ... A. No, I don\u8217\'3ft believe so.\u8221\'3f). Pernix\u8217\'3fs reliance on Dr. Mayersohn\u8217\'3fs testimony on this point is not persuasive. Dr. Mayersohn explained that \u8220\'3f[t]he specifications cite a very specific narrow range of examples with overly broad claims. So the genus and the species associated with the genus, I believe, are not well defined.\u8221\'3f 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 133:18\u8211\'3f22. More importantly, the fact that the claims encompass both Devane\u8217\'3fs and Huang\u8217\'3fs formulations is sufficient reason for 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Clarke
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 to apply.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Finally, Pernix notes that 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Clarke
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 instructs that \u8220\'3fall the applicant can be required to show is priority with respect to so much of the claimed invention as the reference happens to show.\u8221\'3f Dkt. No. 185, at 1 (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1965100976&pubNum=0000350&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_350_989&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_350_989" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Clarke
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 356 F.2d at 989
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
). Under that standard, Pernix argues that Huang is not prior art because it does not show all of the following: a \u8220\'3fpatient having mild or moderate 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8221\'3f; \u8220\'3ftreating pain\u8221\'3f in such a patient; administering to such a patient \u8220\'3fa starting dose of an oral dosage unit ... wherein the starting dose is not adjusted relative to a patient without 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8221\'3f; or any release profile data for hepatically impaired patients. Dkt. No. 185, at 2. However, Pernix has 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Clarke
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 backwards: To antedate a reference, the patentee needs to show that the inventors possessed knowledge of the species contained in both the reference and the patent, 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
not
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 to show that the invention is broader than the reference. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1965100976&pubNum=0000350&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_350_991&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_350_991" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Clarke
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 356 F.2d at 991
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3f[I]t it is not the entire scope of the claims which is determinative of the issue here. Rather, it is how much the reference shows of the claimed invention that is crucial to the requirement of what the affidavit must show.\u8221\'3f); 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
see also
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
In re 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1967101412&pubNum=0000350&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_350_284&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_350_284" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
DaFano
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 392 F.2d 280, 284 (CCPA 1968)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3f[In 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Clarke
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, we] set forth, as a test for the adequacy of the affidavit, a standard of whether the showing would convince one of ordinary skill in the art to a reasonable certainty that the applicant possessed so much of the invention as to encompass the reference disclosure
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.... It is necessary that the species which were reduced to practice provide an adequate basis for inferring that the invention has generic applicability.\u8221\'3f). Pernix\u8217\'3fs argument that Huang does not disclose additional limitations in the patents-in-suit does not focus on the proper question under 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Clarke
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 with respect to the factual issues of inherent anticipation or obviousness.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_17_53}{\*\bkmkend co_pp_sp_999_17_53}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*17
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 For these reasons, the Court finds that, in light of the analysis required by the decision in 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Clarke
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, there are disputes of fact that preclude a determination as to whether the inventors reduced the species disclosed in Huang to practice as of November 2, 2011, so as to preclude Huang from serving as prior art. Alvogen\u8217\'3fs motion for summary judgment of anticipation must therefore be denied with respect to Huang.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ib637ed51a3fe11e99db4e63a0d33c}{\*\bkmkend co_anchor_Ib637ed51a3fe11e99db4e63a0d33c}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
B. Anticipation by Devane
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Alvogen argues that Devane inherently anticipates all of the asserted claims. Devane is a published patent application entitled \u8220\'3fMultiparticulate Modified Release Composition.\u8221\'3f It is directed to a controlled release composition that provides both immediate and delayed release of the active ingredient or ingredients. Dkt. No. 122\u8211\'3f3 \u182\'3f 26. Devane teaches that its \u8220\'3fmodified release composition\u8221\'3f can be used with 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3bd96eea475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hydrocodone
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 to provide continuous analgesia for up to 24 hours. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u182\'3f 70. It provides an example of a 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3bd96eea475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hydrocodone
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 bitartrate modified release composition with six possible immediate release components and seven possible modified release components. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u182\'3f\u182\'3f 99\u8211\'3f102.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Devane also describes the results of an in vivo study using one of those formulations, and it provides the pharmacokinetic results from that study. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u182\'3f\u182\'3f 103\u8211\'3f05. The dosage formulation disclosed in Devane\u8217\'3fs in vivo study is identical to the dosage formulation disclosed in the patents-in-suit and contained in the product that has been commercialized by Pernix under the name Zohydro ER. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u182\'3f\u182\'3f 104\u8211\'3f05 (Tables 6 and 7, disclosing immediate and modified released components); \u8217\'3f706 patent, col. 22, ll. 50\u8211\'3f58 (describing the clinical study performed to determine the influence of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 of controlled release 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3bd96eea475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hydrocodone
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 prepared according to the formulations from Devane); Dkt. No. 163\u8211\'3f3, at 3\u8211\'3f8 (Pernix\u8217\'3fs responses to Alvogen\u8217\'3fs requests for admission).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
To anticipate a patent claim, a single prior art reference must contain all of the limitations of the asserted claim, either explicitly or inherently. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2012079141&pubNum=0000506&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_506_1378&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1378" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
In re Omeprazole Patent Litig.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 483 F.3d 1364, 1378 (Fed. Cir. 2007)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. In order to establish inherent anticipation, any missing limitations must necessarily be present in the prior art, not merely probably or possibly present. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2002413412&pubNum=0000506&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_506_1295&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1295" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Trintec Indus., Inc. v. Top\u8211\'3fU.S.A. Corp.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 295 F.3d 1292, 1295 (Fed. Cir. 2002)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1991186642&pubNum=0000350&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_350_1268&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_350_1268" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Continental Can Co. v. Monsanto Co.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 948 F.2d 1264, 1268\u8211\'3f69 (Fed. Cir. 1991)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. If the prior art reference \u8220\'3fnecessarily functions in accordance with, or includes, the claimed limitations, it anticipates.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1999205673&pubNum=0000506&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_506_1347&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1347" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Atlas Powder Co. v. Ireco, Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 190 F.3d 1342, 1347 (Fed. Cir. 1999)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1986147440&pubNum=0000350&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_350_1326&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_350_1326" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
In re King
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 801 F.2d 1324, 1326 (Fed. Cir. 1986)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 ). In general, \u8220\'3fthe discovery of a previously unappreciated property of a prior art composition, or of a scientific explanation for the prior art\u8217\'3fs functioning, does not render the old composition patentably new to the discoverer.\u8221\'3f 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
\par 
}
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The parties do not dispute that Devane discloses using the same extended release 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3bd96eea475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hydrocodone
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 formulation that is described in the patents-in-suit to treat pain. In addition, the parties agree that Devane discloses the pharmacokinetic profile of that 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3bd96eea475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hydrocodone
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 formulation in healthy patients. Finally, the parties do not dispute that Devane is silent on the issue of treating patients with 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00052044540857_ID0EMVBI_53}{\*\bkmkend co_fnRef_B00052044540857_ID0EMVBI_53}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00052044540857_53" }{\fldrslt 
{\super \b0 \cf23 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
5
}}}
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_18_53}{\*\bkmkend co_pp_sp_999_18_53}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*18
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Each claim at issue recites a \u8220\'3fmethod of treating pain in a patient having mild or moderate 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
,\u8221\'3f the method comprising \u8220\'3fadministering to the patient having mild or moderate 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 an oral dosage unit having 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3bd96eea475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hydrocodone
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 bitartrate as the only active ingredient,\u8221\'3f and that the \u8220\'3fdosage unit comprises an extended release formulation of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3bd96eea475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hydrocodone
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 bitartrate.\u8221\'3f Claim 1 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038345875&pubNum=0004074&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=PA&docFamilyGuid=I0828fca0db3d11e58e7d9ad815219c93&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f760 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 further provides that \u8220\'3fthe starting dose is not adjusted relative to a patient without 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.\u8221\'3f Dependent claims 2, 3, 4, and 11 each add aspects of the release profile for the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3bd96eea475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hydrocodone
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 formulation. Similarly, claims 12, 17, and 19 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038345875&pubNum=0004074&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=PA&docFamilyGuid=I0828fca0db3d11e58e7d9ad815219c93&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f760 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and claim 1 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038908796&pubNum=0004074&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=PA&docFamilyGuid=I994d8600212511e6a515da1203855afb&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f499 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 recite aspects of the release profile of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3bd96eea475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hydrocodone
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 formulation, such as that the dosage unit \u8220\'3fdoes not increase average 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3bd96eea475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hydrocodone
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 AUC
}
{\b0 \cf1 \f2 \i0 \fs16 
{\sub \b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
0\u8211\'3finf
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 in subjects suffering from mild 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 relative to subjects not suffering from 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ica87e4b0475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
renal
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 or 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 in an amount of more than 14%.\u8221\'3f
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Federal Circuit case law is clear that the pharmacokinetic features of particular compounds are inherent properties of those compounds that \u8220\'3fadd[ ] nothing of patentable consequence\u8221\'3f when claimed as limitations. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2025286181&pubNum=0000506&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_506_1070&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1070" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
In re Kao
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 639 F.3d 1057, 1070 (Fed. Cir. 2011)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
see also
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2028528196&pubNum=0000506&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_506_1354&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1354" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Santarus, Inc. v. Par Pharm., Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 694 F.3d 1344, 1354 (Fed. Cir. 2012)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fThe initial blood serum concentration resulting from administering a PPI dosage is an inherent property of the formulation, and an obvious formulation cannot become nonobvious simply by administering it to a patient and claiming the resulting serum concentrations.\u8221\'3f); 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
see also
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034906582&pubNum=0000506&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_506_1195&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1195" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
PAR Pharm., Inc. v. TWI Pharm., Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 773 F.3d 1186, 1195\u8211\'3f96 (Fed. Cir. 2014)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (inherency in an obviousness analysis may be found where the property is \u8220\'3fnecessarily present\u8221\'3f or \u8220\'3fthe natural result of the combination of elements explicitly disclosed by the prior art\u8221\'3f). 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
See generally 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1945114606&pubNum=0000780&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_780_249&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_249" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Gen. Elec. Co. v. Jewel Incandescent Lamp Co.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 326 U.S. 242, 249 (1945)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fIt is not invention to perceive that the product which others had discovered had qualities they failed to detect.\u8221\'3f).
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00062044540857_ID0EZ4BI_53}{\*\bkmkend co_fnRef_B00062044540857_ID0EZ4BI_53}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00062044540857_53" }{\fldrslt 
{\super \b0 \cf23 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
6
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Accordingly, Devane inherently anticipates the release profile limitations.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Devane recites a method \u8220\'3ffor the treatment of pain comprising administering a therapeutically effective amount\u8221\'3f of a \u8220\'3fmultiparticulate modified release composition\u8221\'3f containing 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3bd96eea475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hydrocodone
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 as the active ingredient, in which the composition is delivered orally. Dkt. No. 122\u8211\'3f3, cl. 81 (depending on claims 1 and 17). Devane is silent, however, as to the treatment or dosing of patients having mild or moderate 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, and Pernix points to evidence in the record that the testing on which Devane was based was performed on healthy patients not including hepatically impaired individuals. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Dkt. No. 142\u8211\'3f1, \u182\'3f\u182\'3f 67\u8212\'3f77 (Dr. Gudin\u8217\'3fs assessment that the study underlying Devane did not include hepatically impaired patients); Dkt. No. 146\u8211\'3f1, Ex. N (the report on the clinical study underlying Devane). Accordingly, the parties disagree about whether Devane inherently discloses either treating hepatically impaired individuals for pain, or administering an extended release 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3bd96eea475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hydrocodone
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 composition to patients with mild or moderate 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 without adjusting the starting dose relative to patients without 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The Federal Circuit has addressed cases in which a prior art reference describes a broad treatment method and the claimed invention is directed to a narrow subset of patients, and it has analyzed those types of cases as presenting genus-species issues. 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
For example, in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2037563178&pubNum=0000506&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Prometheus Laboratories, Inc. v. Roxane Laboratories, Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 805 F.3d 1092 (Fed. Cir. 2015)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the Federal Circuit affirmed a district court\u8217\'3fs finding of obviousness of a claim directed at treating 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic8ee0a9e475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
irritable bowel
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 syndrome (\u8220\'3fIBS\u8221\'3f) in a subset of patients\u8212\'3f\u8220\'3fthose who (1) are women (2) with IBS\u8211\'3fD (3) who have experienced symptoms for at least six months and (4) who have had moderate pain\u8221\'3f\u8212\'3fin light of a prior art reference that disclosed the same treatment for IBS generally. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2037563178&pubNum=0000506&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_506_1098&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1098" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1098
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The court explained:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_19_53}{\*\bkmkend co_pp_sp_999_19_53}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*19
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 The genus-species distinction may have particular relevance in the field of personalized medicine, where, for example, a particular treatment may be effective with respect to one subset of patients and ineffective (and even harmful) to another subset of patients. Singling out a particular subset of patients for treatment (for example, patients with a particular gene) may reflect a new and useful invention that is patent eligible despite the existence of prior art or a prior art patent disclosing the treatment method to patients generally. An obviousness rejection likely would not be appropriate where the new patient subset displayed unexpected results.
\par 
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1099 (citation omitted). Similarly, in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034175495&pubNum=0000506&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Abbvie Inc. v. Mathilda and Terence Kennedy Institute of Rheumatology Trust
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 764 F.3d 1366 (Fed. Cir. 2014)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the patent-in-suit claimed treating patients with \u8220\'3factive disease,\u8221\'3f while the prior art taught the genus of treating patients \u8220\'3fin need\u8221\'3f of treatment. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034175495&pubNum=0000506&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_506_1369&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1369" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1369\u8211\'3f70
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. There, too, the Federal Circuit considered the treatment of a narrowly defined population of patients as a species of the broad genus consisting of the treatment of patients generally, and the court concluded that the species claims would have been obvious in light of the prior art reference regarding the applicable genus. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034175495&pubNum=0000506&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_506_1378&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1378" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
id.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1378\u8211\'3f80
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
As a general matter, a prior art reference that discloses a genus \u8220\'3fdoes not inherently disclose all species within that broad category.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2004552102&pubNum=0000506&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_506_1367&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1367" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Metabolite Labs., Inc. v. Lab. Corp. of Am. Holdings
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 370 F.3d 1354, 1367 (Fed. Cir. 2004)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. In such a case, \u8220\'3fthe issue of anticipation turns on whether the genus was of such a defined and limited class that one of ordinary skill in the art could \u8216\'3fat once envisage\u8217\'3f each member of the genus.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027963018&pubNum=0000506&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_506_1361&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1361" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Wm. Wrigley Jr. Co. v. Cadbury Adams USA LLC
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 683 F.3d 1356, 1361 (Fed. Cir. 2012)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2010984122&pubNum=0000506&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_506_1376&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1376" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Eli Lilly & Co. v. Zenith Goldline Pharm., Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 471 F.3d 1369, 1376 (Fed. Cir. 2006)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 ). In order to find that a generic disclosure anticipates a species within that genus, the generic reference must identify the claimed species with \u8220\'3fsufficient specificity\u8221\'3f; that is, the reference must express \u8220\'3fspecific preferences\u8221\'3f for one or more particular species or must disclose a genus that is sufficiently small such that the disclosure of the genus effectively describes the species. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034175495&pubNum=0000506&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_506_1379&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1379" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Abbvie
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 764 F.3d at 1379
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2001324901&pubNum=0000506&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_506_1380&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1380" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Bristol\u8211\'3fMyers Squibb Co. v. Ben Venue Labs., Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 246 F.3d 1368, 1380 (Fed. Cir. 2001)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2008742849&pubNum=0000506&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_506_999&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_999" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Atofina v. Great Lakes Chem. Corp.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 441 F.3d 991, 999 (Fed. Cir. 2006)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
In re 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1962103992&pubNum=0000350&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_350_682&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_350_682" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Petering
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 301 F.2d 676, 682\u8211\'3f83 (CCPA 1976)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The question whether a generic reference identifies the claimed species with sufficient specificity is a factual issue. The standard for finding that a prior art genus anticipates an incorporated species is significantly more restrictive than the standard for determining whether a prior art genus renders obvious a species that is incorporated within it. See 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2017647756&pubNum=0000506&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_506_1083&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1083" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Sanofi\u8211\'3fSynthelabo v. Apotex, Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 550 F.3d 1075, 1083\u8211\'3f84 (Fed. Cir. 2008)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Alvogen has not met its burden on summary judgment to show that Devane\u8217\'3fs genus of treating patients for pain inherently anticipates the species of treating hepatically impaired patients for pain. In that regard, it is significant that there is evidence suggesting that the underlying clinical study described in Devane was limited to the treatment of healthy patients. Dkt. No. 141, at 10\u8211\'3f11 (citing Dkt. No. 146\u8211\'3f1, Ex. N). In addition to citing the study itself, Pernix points to testimony elicited from Alvogen\u8217\'3fs expert that if the study had included patients with 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, data regarding those patients would have been described in the study because such patients, like elderly or pediatric patients, are often considered \u8220\'3fspecial population[s].\u8221\'3f Dkt. No. 141, at 11; 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
see
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Dkt. No. 146\u8211\'3f1, Ex. D, at 112:10\u8211\'3f18 (Alvogen\u8217\'3fs expert testifying that \u8220\'3fif any of the patients had 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, ... it is highly likely that that would have been revealed in the Devane document\u8221\'3f).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_20_53}{\*\bkmkend co_pp_sp_999_20_53}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*20
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Alvogen argues that the population of pain patients receiving treatment using Devane\u8217\'3fs formulation will \u8220\'3finevitably include[ ] patients with mild or moderate\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Dkt. No. 119, at 14 (citing Dkt. No. 122\u8211\'3f12, at 27:23\u8211\'3f29:9). That argument, however, does not reflect what Devane inherently teaches, particularly in light of the evidence that the study underlying Devane\u8217\'3fs application did not include hepatically impaired patients. Drawing all reasonable inferences in Pernix\u8217\'3fs favor, Alvogen has not met its burden of showing that there is no dispute of fact as to whether Devane specifically discloses treating pain in patients with mild or moderate 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
This analysis is consistent with the Federal Circuit\u8217\'3fs decision in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2007917386&pubNum=0000506&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Perricone v. Medicis Pharmaceutical Corp.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 432 F.3d 1368 (Fed. Cir. 2005)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, on which Alvogen heavily relies. In 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Perricone
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the prior art reference taught a cosmetic composition for topical application; the reference disclosed a variety of ingredients that, when applied topically, have beneficial effects on the skin. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2007917386&pubNum=0000506&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_506_1376&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1376" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1376
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The asserted independent claims of the patent in suit recited methods for: \u8220\'3ftreating skin sunburn comprising topically applying to the skin sunburn ...\u8221\'3f; \u8220\'3fpreventing sunburn damage to exposed skin surfaces, comprising topically applying to said skin surfaces ...\u8221\'3f; \u8220\'3fthe treatment of skin disorders which arise because of depleted or inhibited collagen synthesis which comprises topically applying to affected skin areas ...\u8221\'3f; \u8220\'3fthe treatment of skin damaged or aged by ... which comprises topically applying to affected skin areas a composition containing ...\u8221\'3f; and \u8220\'3fthe treatment of damaged or aging skin and epithelial tissue disorders ... said treatment comprising topically applying to affected tissue areas the combination of ....\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2007917386&pubNum=0000506&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_506_1378&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1378" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1378
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (alterations in original).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
All three judges on the 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Perricone
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 panel agreed that the prior art inherently anticipated the claims that \u8220\'3fmerely require[d] application of the composition to exposed skin surfaces.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2007917386&pubNum=0000506&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_506_1379&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1379" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1379
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
see also
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2007917386&pubNum=0000506&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_506_1381&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1381" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
id.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1381
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (Bryson, J., concurring in part and dissenting in part). However, the panel majority distinguished the claims that were limited to applying lotion to sunburned skin, which was a narrower application that was not disclosed in the prior art reference. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2007917386&pubNum=0000506&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_506_1379&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1379" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1379
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (majority opinion). Just as the prior art did not disclose applying lotion to sunburned skin, Devane may not inherently disclose treating pain in patients with mild or moderate 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, at least in the absence of evidence to the contrary regarding the Devane reference.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Alvogen also argues that this case is identical to 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2008313252&pubNum=0004637&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Aventis Pharmaceuticals, Inc. v. Barr Laboratories, Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 411 F. Supp. 2d 490 (D.N.J. 2006)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
aff\u8217\'3fd
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 208 Fed.Appx. 842, 208 Fed.Appx. 843 (Fed. Cir. 2006) (per curiam summary affirmances). The patent-in-suit in that case recited a \u8220\'3fmethod of treating a histamine-mediated condition in a patient having impaired liver function due to disease or due to administration of a concomitant drug which inhibits normal liver metabolic function while avoiding cardiac events associated with the administration of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3b37b048475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
terfenadine
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, said method comprising administering to said patient an effective antihistaminic amount of\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3c66ba7d475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
fexofenadine
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2008313252&pubNum=0004637&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_4637_519&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_4637_519" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 519
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The prior art patent claimed a \u8220\'3fmethod of treating 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib3eefb95475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
allergic reactions
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 in a patient in need thereof which comprises administering to said patient an effective amount of\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3c66ba7d475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
fexofenadine
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 On a motion for a preliminary injunction, the district court in 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Aventis
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 denied preliminary injunctive relief based in part on a finding that the defendants had \u8220\'3fraised a substantial question of invalidity.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2008313252&pubNum=0004637&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_4637_518&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_4637_518" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 518
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. On an interlocutory appeal from that denial, the Federal Circuit summarily affirmed without opinion. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2010683729&pubNum=0006538&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Aventis Pharm., Inc. v. Barr Labs., Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 208 Fed.Appx. 843 (Fed. Cir. 2006)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_21_53}{\*\bkmkend co_pp_sp_999_21_53}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*21
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Although there are several similarities between 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Aventis
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and the present case, the district court\u8217\'3fs decision in 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Aventis
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is not dispositive here, for several reasons. First, the 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Aventis
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 court found, as a factual matter, and under the \u8220\'3freasonable likelihood of success\u8221\'3f standard, that the \u8220\'3fcharacteristic of treating hepatically impaired patients is necessarily present in the teaching\u8221\'3f of the prior art reference that \u8220\'3fdiscloses a method for treating all patients.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2008313252&pubNum=0004637&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_4637_522&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_4637_522" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 522
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Second, the issue of inherent anticipation was raised in the context of a preliminary injunction, and thus the issue of anticipation was not conclusively decided at that time. The applicable standards for granting preliminary injunctive relief and granting summary judgment are, of course, quite different. Finally, the district court\u8217\'3fs decision in 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Aventis
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 was issued in 2006, and the court therefore did not have the benefit of the Federal Circuit\u8217\'3fs subsequent decisions in cases such as 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Prometheus Laboratories
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Abbvie
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
For purposes of trial, the Court notes that Pernix\u8217\'3fs argument that inherent anticipation requires that the \u8220\'3fmissing descriptive matter is necessarily present in the thing described in the reference, and that it would be so recognized by persons of ordinary skill\u8221\'3f is, at best, only partially true. Dkt. No. 141, at 19 (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1991186642&pubNum=0000350&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_350_1269&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_350_1269" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Continental Can
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 948 F.2d at 1269\u8211\'3f69
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
). The Federal Circuit has clarified that 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Continental Can
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 does not require \u8220\'3fthat an inherent feature of a prior art reference must be perceived as such by a person of ordinary skill in the art before the critical date.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2003535318&pubNum=0000506&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_506_1377&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1377" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Schering Corp. v. Geneva Pharm., Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 339 F.3d 1373, 1377 (Fed. Cir. 2003)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Rather, when read in context, 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Continental Can
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 held that \u8220\'3finherency, like anticipation itself, requires a determination of the meaning of the prior art.\u8221\'3f 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 A court therefore may \u8220\'3fconsult artisans of ordinary skill to ascertain their understanding about subject matter disclosed by the prior art, including features inherent in the prior art\u8221\'3f and may \u8220\'3fresolve factual questions about the subject matter in the prior art by examining the reference through the eyes of a person of ordinary skill in the art, among other sources of evidence about the meaning of the prior art.\u8221\'3f
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2003535318&pubNum=0000506&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_506_1377&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1377" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1377\u8211\'3f78
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
see also, e.g.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2012079141&pubNum=0000506&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_506_1373&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1373" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
In re Omeprazole Patent Litigation
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 483 F.3d 1364, 1373 (Fed. Cir. 2007)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3f[I]nherency is not necessarily coterminous with knowledge of those of ordinary skill in the art. Artisans of ordinary skill may not recognize the inherent characteristics or functioning of the prior art\u8221\'3f (quoting 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
In re 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2002529055&pubNum=0000506&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_506_1349&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1349" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Cruciferous Sprout Litig.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 301 F.3d 1343, 1349 (Fed. Cir. 2002)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 ) ); 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2010622428&pubNum=0000506&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_506_1367&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1367" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Abbott Labs v. Baxter Pharm. Prods.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 471 F.3d 1363, 1367 (Fed. Cir. 2006)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fOur cases have consistently held that a reference may anticipate even when the relevant properties of the thing disclosed were not appreciated at the time.\u8221\'3f); 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2006436300&pubNum=0000506&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_506_1343&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1343" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
SmithKline Beecham Corp. v. Apotex Corp.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 403 F.3d 1331, 1343 (Fed. Cir. 2005)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3f[I]nherent anticipation does not require a person of ordinary skill in the art to recognize the inherent disclosure in the prior art at the time the prior art is created.\u8221\'3f); 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2004073909&pubNum=0000506&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_506_1321&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1321" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Toro Co. v. Deere & Co.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 355 F.3d 1313, 1321 (Fed. Cir. 2004)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fSimply put, the fact that a characteristic is a necessary feature or result of a prior-art embodiment (that is itself sufficiently described and enabled) is enough for inherent anticipation, even if that fact was unknown at the time of the prior invention.\u8221\'3f).
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00072044540857_ID0EEADI_53}{\*\bkmkend co_fnRef_B00072044540857_ID0EEADI_53}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00072044540857_53" }{\fldrslt 
{\super \b0 \cf23 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
7
}}}
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_22_53}{\*\bkmkend co_pp_sp_999_22_53}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*22
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 For the reasons stated above, Alvogen\u8217\'3fs motion for summary judgment of invalidity by anticipation, Dkt. No. 115, is DENIED.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ib64ab201a3fe11e99db4e63a0d33c}{\*\bkmkend co_anchor_Ib64ab201a3fe11e99db4e63a0d33c}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
IV. The Cross\u8211\'3fMotions for Summary Judgment as to Patent Eligibility
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The parties have filed cross-motions for summary judgment addressing whether the asserted claims of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038345875&pubNum=0004074&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=PA&docFamilyGuid=I0828fca0db3d11e58e7d9ad815219c93&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f760
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038908796&pubNum=0004074&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=PA&docFamilyGuid=I994d8600212511e6a515da1203855afb&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f499 patents
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 satisfy the requirements of the patent eligibility statute, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Dkt. Nos. 111, 114.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
As articulated by the Supreme Court, the analysis of patent eligibility under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
section
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 entails two steps. Step one requires the Court to \u8220\'3fdetermine whether the claims at issue are directed to a patent-ineligible concept\u8221\'3f such as a natural law or an abstract idea. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_708_2355&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2355" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Alice Corp. Pty. v. CLS Bank Int\u8217\'3fl
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 134 S. Ct. 2347, 2355 (2014)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. If so, the Court proceeds to step two, which requires the Court \u8220\'3fto consider the elements of each claim both individually and \u8216\'3fas an ordered combination\u8217\'3f to determine whether the additional elements \u8216\'3ftransform the nature of the claim\u8217\'3f into a patent-eligible application.\u8221\'3f 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_780_78&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_78" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Mayo Collaborative Servs. v. Prometheus Labs., Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 566 U.S. 66, 78\u8211\'3f79 (2012)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 ). In that step, the Court searches \u8220\'3ffor an \u8216\'3finventive concept\u8217\'3f\u8212\'3fi.e., an element or combination of elements that is \u8216\'3fsufficient to ensure that the patent in practice amounts to significantly more than a patent upon the [ineligible concept] itself.\u8217\'3f \u8221\'3f 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (alteration in original) (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_780_72&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_72" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 566 U.S. at 72\u8211\'3f73
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Alvogen argues that the asserted claims of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038345875&pubNum=0004074&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=PA&docFamilyGuid=I0828fca0db3d11e58e7d9ad815219c93&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f760
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038908796&pubNum=0004074&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=PA&docFamilyGuid=I994d8600212511e6a515da1203855afb&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f499 patents
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 are ineligible for patent protection under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
section
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 because they are \u8220\'3fpremised on the relationship between [
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
] and the bioavailability of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3bd96eea475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hydrocodone
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 in the body after administration of Devane\u8217\'3fs [extended release 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3bd96eea475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hydrocodone
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
] prior art formulation\u8212\'3fnamely that the response of the human body to this formulation is similar in patients with and without mild or moderate [
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
].\u8221\'3f Dkt. No. 112, at 11; 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
see also
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Dkt. No. 145, at 3.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The claims asserted in this case are distinguishable from the claim examined by the Supreme Court in 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, a decision on which Alvogen heavily relies. In 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the representative claim recited a two-step method that involved administering a known drug and using routine processes to determine the level of a certain metabolite. The claim also included a wherein clause that identified the significance of metabolite level. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_780_74&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_74" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 566 U.S. at 74\u8211\'3f75
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The Supreme Court explained that the wherein clause \u8220\'3fat most add[ed] a suggestion that [doctor] should take those [natural] laws into account when treating his patient ... while trusting [the doctor] to use those laws appropriately where they are relevant to their decisionmaking.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_780_78&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_78" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 78
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The Court distinguished the claim at issue in 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 from \u8220\'3fa typical patent on a new drug or a new way of using an existing drug,\u8221\'3f on the ground that the claims before the Court \u8220\'3fadd[ed] nothing of significance to the natural laws themselves.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_780_87&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_87" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 87
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
see also
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2044320422&pubNum=0000506&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_506_1134&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1134" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Vanda Pharm.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 887 F.3d at 1134
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fAlthough the representative claim in 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 recited administering a thiopurine drug to a patient, the claim as a whole was not directed to the application of a drug to treat a particular disease.\u8221\'3f).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_23_53}{\*\bkmkend co_pp_sp_999_23_53}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*23
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Two recent decisions of the Federal Circuit are instructive in this regard. In 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039315377&pubNum=0000506&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Rapid Litigation Management Ltd. v. CellzDirect, Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 827 F.3d 1042 (Fed. Cir. 2016)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the inventors of the patent at issue had discovered that hepatocytes, a type of liver cell, could survive multiple freeze-thaw cycles. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039315377&pubNum=0000506&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_506_1050&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1050" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1050
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The representative claim recited a \u8220\'3fmethod of producing a desired preparation of multi-cryopreserved hepatocytes.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039315377&pubNum=0000506&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_506_1046&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1046" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1046
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Although the representative claim applied a natural property of hepatocytes, \u8220\'3fthat is not where [the inventors] stopped, nor is it what they patented.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039315377&pubNum=0000506&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_506_1048&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1048" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1048
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Rather, \u8220\'3f \u8216\'3fas the first party with knowledge of\u8217\'3f the cells\u8217\'3f ability, they were \u8216\'3fin an excellent position to claim applications of that knowledge.\u8217\'3f \u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039315377&pubNum=0000506&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_506_1048&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1048" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1048
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030717666&pubNum=0000780&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_780_596&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_596" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Ass\u8217\'3fn for Molecular Pathology v. Myriad Genetics, Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 569 U.S. 576, 596 (2013)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 ). Instead of claiming \u8220\'3fnothing more than observing or identifying the ineligible concept itself,\u8221\'3f the inventors \u8220\'3femployed their natural discovery to create a new and improved way of preserving hepatocyte cells for later use.\u8221\'3f 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
see also
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039315377&pubNum=0000506&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_506_1048&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1048" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
id.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1048
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fThrough the recited steps, the patented invention achieves a better way of preserving hepatocytes.\u8221\'3f).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
CellzDirect
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 court concluded that patents that \u8220\'3frecite processes to achieve a desired outcome, e.g., methods of producing things, or methods of treating disease\u8221\'3f are generally not patent-ineligible. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039315377&pubNum=0000506&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_506_1048&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1048" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1048\u8211\'3f49
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. If it were otherwise, \u8220\'3fwe would find patent-ineligible methods of, say, producing a new compound (as directed to the individual components\u8217\'3f ability to combine to form the new compound), treating 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Iaf34f5c3475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
cancer
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 with chemotherapy (as directed to 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Iaf34f5c3475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
cancer
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 cells\u8217\'3f inability to survive chemotherapy), or treating headaches with 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3af17fb7475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
aspirin
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (as directed to the human body\u8217\'3fs natural response to 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3af17fb7475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
aspirin
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
).\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039315377&pubNum=0000506&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_506_1049&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1049" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1049
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Similarly, in 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Vanda Pharmaceuticals, Inc. v. West\u8211\'3fWard Pharmaceuticals International Ltd.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the Federal Circuit held that a method of treatment claim that adjusted dosage based on whether the patient had normal or lower enzyme activity was patent-eligible under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
section
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2044320422&pubNum=0000506&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_506_1121&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1121" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
887 F.3d at 1121
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The representative claim recited a \u8220\'3fmethod for treating a patient with iloperidone, wherein the patient is suffering from 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic8ad584c475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
schizophrenia
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.\u8221\'3f 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 The claim required two steps: first, determining the patient\u8217\'3fs metabolizer genotype \u8220\'3fby (a) obtaining a biological sample and (b) performing a 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Ib3510dc6475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
genotyping
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 assay\u8221\'3f; and second, \u8220\'3fadministering specific dose ranges of iloperidone depending on the patient\u8217\'3fs\u8221\'3f genotype. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2044320422&pubNum=0000506&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_506_1134&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1134" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1134
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The court held that the claims at issue in 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Vanda
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 were \u8220\'3fdirected to a method of using iloperidone to treat 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic8ad584c475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
schizophrenia
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8221\'3f and not a natural law. Distinguishing 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the court emphasized that the \u8220\'3finventors recognized the relationships between iloperidone, CYP2D6 metabolism, and QTc prolongation, but that is not what they claimed. They claimed an application of that relationship.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2044320422&pubNum=0000506&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_506_1135&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1135" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1135
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Unlike the claim in 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the court explained, \u8220\'3f[t]hese are treatment steps\u8221\'3f that are \u8220\'3fdirected to a specific method of treatment for specific patients using a specific compound at specific doses to achieve a specific outcome.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2044320422&pubNum=0000506&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_506_1135&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1135" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1135\u8211\'3f36
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The independent claims asserted in this case are indistinguishable from the representative claim discussed in 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Vanda
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Claim 1 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038345875&pubNum=0004074&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=PA&docFamilyGuid=I0828fca0db3d11e58e7d9ad815219c93&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f760 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 recites a \u8220\'3fmethod of treating pain in a patient having mild or moderate 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
,\u8221\'3f and teaches using an extended release formulation of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3bd96eea475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hydrocodone
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 bitartrate wherein the \u8220\'3fstarting dose is not adjusted relative to a patient without 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.\u8221\'3f Claim 12 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038345875&pubNum=0004074&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=PA&docFamilyGuid=I0828fca0db3d11e58e7d9ad815219c93&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f760 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and claim 1 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038908796&pubNum=0004074&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=PA&docFamilyGuid=I994d8600212511e6a515da1203855afb&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f499 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 each recites a \u8220\'3fmethod of treating pain in a patient having mild or moderate 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hepatic impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
,\u8221\'3f and teaches using a specific extended release formulation of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3bd96eea475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hydrocodone
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 bitartrate that has a particular release profile. Although the inventions recited in those claims were based upon a natural law\u8212\'3fthe physiological response to 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3bd96eea475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hydrocodone
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 in individuals with or without mild or moderate hepatic impairment\u8212\'3fthe claims do more than merely report those physiological responses. Rather, like the claim discussed in 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Vanda
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the claims asserted in this case describe a specific dosing regimen to treat a specific condition based on the patient\u8217\'3fs medical status.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_24_53}{\*\bkmkend co_pp_sp_999_24_53}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*24
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Alvogen contends that the opposite result is compelled by the decisions in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2037233525&pubNum=0000999&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Endo Pharmaceuticals Inc. v. Actavis Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3f
}
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Endo I
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8221\'3f), No. 14\u8211\'3fcv\u8211\'3f1381, 2015 WL 5580488 (D. Del. Nov. 17, 2015)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
report and recommendation adopted by 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2037607836&pubNum=0000999&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Endo Pharmaceuticals Inc. v. Actavis Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3f
}
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Endo II
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8221\'3f), No. 14\u8211\'3fcv\u8211\'3f1381, 2015 WL 7253674 (D. Del. Sept. 23, 2015)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. In that case, a representative claim recited a \u8220\'3fmethod for treating pain in a renally impaired patient\u8221\'3f that required: (1) providing an oral controlled release dosage form of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3c672fd9475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
oxymorphone
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; (2) measuring the patient\u8217\'3fs 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Ic9820d4d475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
creatinine clearance rate
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; and (3) administering a lower dosage, based on the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Iab95ae98475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
creatinine
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 rate, so as to not exceed a maximum total drug exposure over time. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2037233525&pubNum=0000999&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Endo I
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 2015 WL 5580488, at *1\u8211\'3f2
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Endo
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 opinions do not support Alvogen\u8217\'3fs position. First, as acknowledged in both decisions, the patentee effectively conceded that the claim was directed to a natural law. 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at *6 (\u8220\'3fIndeed, plaintiffs effectively concede the first step of the 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 analysis.\u8221\'3f); 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2037607836&pubNum=0000999&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Endo II
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 2015 WL 7253674 at *3
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fAs the Magistrate Judge points out, Plaintiffs essentially admitted in their briefing that the \u8217\'3f737 patent claims a natural law as its invention.\u8221\'3f). Moreover, the representative claim in 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Endo
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is more akin to the claim in 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 than to the claims at issue in 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
CellzDirect
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Vanda
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, and this case. As in 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the claim at issue in 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Endo
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 in effect simply stated the law of nature\u8212\'3fi.e., renally impaired patients may be more sensitive to oxymorphone\u8212\'3f\u8220\'3fwhile adding the words \u8216\'3fapply it.\u8217\'3f \u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2037607836&pubNum=0000999&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \i0 \fs20 
{\b0 \cf23 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Endo II
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 2015 WL 7253674 at *3
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Finally, to the extent there is any tension between the decisions in 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Endo
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and the subsequently issued Federal Circuit opinions in 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
CellzDirect
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and 
}
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb0 
Vanda
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, those later cases necessarily control.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Because the asserted claims are not directed to a patent-ineligible concept, Pernix\u8217\'3fs motion for summary judgment of no invalidity under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
section
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Dkt. No. 114, is GRANTED, and Alvogen\u8217\'3fs motion for summary judgment of invalidity under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
section
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Dkt. No. 111, is DENIED.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
IT IS SO ORDERED.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf20 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_allCitations_53}{\*\bkmkend co_allCitations_53}
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb200 
All Citations
\par 
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Not Reported in Fed. Supp., 2018 WL 2225113
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
}
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 \par}\sect\sbknone\pgncont\cols1{\ids0 {
{\trowd \ltrrow \trleft0 
\clpadl200 \clpadfl3 \clbrdrt \clbrdrl \trql \clwWidth10080 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs20 \li0 
{\b0 \cf1 \f4 \i0 \fs20 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Footnotes
\par 
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \ql \li0 \fs20 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B00012044540857_53}{\*\bkmkend co_footnote_B00012044540857_53}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00012044540857_ID0EYPAG_53" }{\fldrslt 
{\super \b0 \cf23 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
1
}\super \b0 \cf23 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
The Court does not discuss Pernix\u8217\'3fs struck patient-only theory of direct infringement.
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B00022044540857_53}{\*\bkmkend co_footnote_B00022044540857_53}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00022044540857_ID0ESEAI_53" }{\fldrslt 
{\super \b0 \cf23 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
2
}\super \b0 \cf23 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
The fact that this is a summary judgment proceeding in a case that will be tried to the Court requires the Court to engage in a somewhat artificial exercise: for purposes of summary judgment, the Court is required to determine, drawing all reasonable inferences in Alvogen\u8217\'3fs favor, whether the evidence of inducement proffered during the summary judgment proceedings is sufficient to require a finding of inducement as a matter of law; whereas after trial, the Court will be required to determine whether the evidence of inducement offered at trial is sufficient to require a finding of inducement as a matter of fact. Given the different nature of the inquiry at those two procedural steps, and the different evidence that the Court is likely to have before it at each stage, the Court could well reach a different result on the factual issue following the trial.
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B00032044540857_53}{\*\bkmkend co_footnote_B00032044540857_53}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00032044540857_ID0EDIAI_53" }{\fldrslt 
{\super \b0 \cf23 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
3
}\super \b0 \cf23 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
For the same reason, the Court has denied Pernix\u8217\'3fs motion in limine to preclude Alvogen from relying on Huang as prior art and Pernix\u8217\'3fs motion in limine to exclude the testimony of Alvogen\u8217\'3fs expert, Dr. Mayersohn, on the ground that his expert report treats Huang as prior art. The Court orally denied both of those motions on the record at the motions hearing held on May 11, 2018.
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B00042044540857_53}{\*\bkmkend co_footnote_B00042044540857_53}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00042044540857_ID0EELAI_53" }{\fldrslt 
{\super \b0 \cf23 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
4
}\super \b0 \cf23 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Huang claims priority to U.S. Provisional Application No. 61/426,306, which was filed on December 22, 2010. Pernix argues that Huang is not entitled to that priority date, because Alvogen has not shown that the provisional application provides support for the claims in Huang in compliance with 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS112&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf19 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf19 \f4 \i0 \fs18 \chcbpat24 
{\b1 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
35
}
}
}
{\b0 \cf23 \f4 \i0 \fs18 \chcbpat2 
}
{\b0 \cf23 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 U.S.C. \u167\'3f 112
}\b0 \cf23 \f4 \ul0 \strike0 \i0 \fs18 \chcbpat2 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
. Dkt. No. 137, at 3 (citing 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2037077796&pubNum=0000506&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_506_1381&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1381" }{\fldrslt 
{\b0 \cf23 \f4 \i0 \fs18 
{\b0 \cf23 \f4 \ul1 \strike0 \i0 \fs18 \sa0 \sb0 
Dynamic Drinkware, LLC v. Nat\u8217\'3fl Graphics, Inc.
}
}
{\b0 \cf23 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, 800 F.3d 1375, 1381 (Fed. Cir. 2015)
}\b0 \cf23 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 ). For purposes of this motion, Alvogen has not argued that Huang is entitled to the filing date of its provisional application. Dkt. No. 164, at 4 n.3.
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B00052044540857_53}{\*\bkmkend co_footnote_B00052044540857_53}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00052044540857_ID0EMVBI_53" }{\fldrslt 
{\super \b0 \cf23 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
5
}\super \b0 \cf23 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
As Pernix notes, Devane is also silent as to the proper dosages for other special populations, such as pregnant women and nursing mothers, populations that are often specifically addressed in drug labels. Dkt. No. 141, at 13 n.6.
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B00062044540857_53}{\*\bkmkend co_footnote_B00062044540857_53}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00062044540857_ID0EZ4BI_53" }{\fldrslt 
{\super \b0 \cf23 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
6
}\super \b0 \cf23 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Of course, if a claim defines the claimed subject matter by its properties rather than, for example, by the chemical name of the compound, it will be the properties that define the scope of the claim. But the mere articulation of newly recognized properties does not in itself make a previously known compound novel.
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \lastrow \trleft0 
\clbrdrb \clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrb \clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B00072044540857_53}{\*\bkmkend co_footnote_B00072044540857_53}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00072044540857_ID0EEADI_53" }{\fldrslt 
{\super \b0 \cf23 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
7
}\super \b0 \cf23 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Alvogen argues that genus-species case law does not apply to inherency because of the case law holding that inherent anticipation does not require recognition by a person of skill prior to the priority date. Dkt. No. 179, at 3\u8211\'3f4. However, Alvogen conflates two separate parts of the anticipation analysis. A property\u8212\'3fsuch as the pharmacokinetic profile in a patient with mild 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib29e3892475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
hepatic impairment
}\b0 \cf23 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 compared to the profile in a patient without hepatic impairment\u8212\'3fmay be found to be inherent when it is \u8220\'3f \u8216\'3fnecessarily present,\u8217\'3f not merely probably or possibly present, in the prior art,\u8221\'3f even if that property was not previously recognized. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2002413412&pubNum=0000506&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_506_1295&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1295" }{\fldrslt 
{\b0 \cf23 \f4 \i0 \fs18 
{\b0 \cf23 \f4 \ul1 \strike0 \i0 \fs18 \sa0 \sb0 
Trintec Indus., Inc. v. Top\u8211\'3fU.S.A. Corp.
}
}
{\b0 \cf23 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, 295 F.3d 1292, 1295 (Fed. Cir. 2002)
}\b0 \cf23 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
. But a modification of a method of treatment is not a \u8220\'3fnecessarily present\u8221\'3f property found in the prior art, and it must be analyzed accordingly. 
}
{\b0 \cf1 \f4 \i0 \fs18 
{\b0 \cf1 \f4 \ul1 \strike0 \i0 \fs18 \sa0 \sb0 
See, e.g.
}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2023571452&pubNum=0000506&originatingDoc=I593a96e0593911e89034f60e1699ddbe&refType=RP&fi=co_pp_sp_506_1055&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1055" }{\fldrslt 
{\b0 \cf23 \f4 \i0 \fs18 
{\b0 \cf23 \f4 \ul1 \strike0 \i0 \fs18 \sa0 \sb0 
AstraZeneca
}
}
{\b0 \cf23 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, 633 F.3d at 1055
}\b0 \cf23 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
.
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }}\par 
}
{\b0 \cf1 \f2 \ri0 \par}\sect\sbknone\pgncont\cols2{\ids0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
}
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 \par}\sect\sbknone\pgncont\cols1{\ids0 {
{\trowd \lastrow \trleft0 
\clpadt24 \clpadft3 \clpadl100 \clpadfl3 \clpadr24 \clpadfr3 \clbrdrt \brdrcf21 \brdrw10 \brdrs \clbrdrb \clbrdrl \trql \clvertalt \clwWidth4320 \cellx4320 
\clpadt29 \clpadft3 \clpadl100 \clpadfl3 \clpadr29 \clpadfr3 \clbrdrt \brdrcf21 \brdrw10 \brdrs \clbrdrb \clbrdrr \trql \clvertalt \clwWidth5760 \cellx10080 
\intbl 
{\ri24 \li24 
{\b1 \cf21 \f4 \ri24 \i0 \ql \fs16 \li24 
{\b1 \cf21 \f4 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
End of Document
\par 
}
}
}\b1 \cf21 \f4 \ri24 \ul0 \strike0 \i0 \ql \li24 \fs16 \sa0 \sb0 \intbl \cell \intbl 
{\ri29 \li29 
{\qr \b0 \cf21 \f4 \ri29 \i0 \fs19 \li29 
{\b0 \cf21 \f4 \ul0 \strike0 \i0 \fs19 \sa0 \sb0 
\u169\'3f 2021 Thomson Reuters. No claim to original U.S. Government Works.
\par 
}
}
}\qr \b0 \cf21 \f4 \ri29 \ul0 \strike0 \i0 \li29 \fs19 \sa0 \sb0 \intbl \cell \row }}\par 
}
{\b0 \cf1 \f2 \ri0 \par}\sect\sbknone\pgncont\cols2{\ids0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
}\sect }